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1.1. DNA Polymerases and their role in replication 
 DNA replication is the process by which genetic material and information 
is copied.  Replication underpins the evolutionary process and is conserved in all 
life yet discovered.  At its simplest, DNA replication is the copying of a template 
DNA by synthesis of a new, complimentary DNA strand1.  This process is carried 
out by a class of enzymes known as polymerases2.   
Polymerases were first discovered by Author Kornberg in 1955 when he 
isolated DNA Polymerase I (Pol I) from E. coli based on the characteristic ability 
to polymerize individual nucleotides3.  Studies on polymerase isolates 
determined that dNTP’s were the building blocks required by polymerases, not 
dNMP’s as were originally thought based on the structure of DNA solved by 
Watson and Crick only a few years earlier1, 3, 4.  Once the polymerase reaction 
was reconstituted in vitro, both Mg2+ and template DNA were found to be 
essential cofactors3.  The requirement for DNA as a cofactor reinforced the 
Watson-Crick and Meselson-Stahl models for replication, using a template strand 
as a guide5, 6.  Finally, the directionality of synthesis was determined to be 5´ to 
3´ only5.   
These core characteristics, defined for the first discovered polymerase, 
Pol I, have remained true for all known DNA polymerases, even as the number of 
known polymerases has expanded7.  Multiple polymerases have been 
discovered within single organisms as well as in each new organism discovered.  
For example, five DNA polymerases have been discovered in E. coli and so far, 
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and 17 in humans8, 9.  In humans, these DNA polymerases are not redundant but 
serve unique roles2.   
The DNA polymerase super-family consists of 7 sub-families: A, B, C, X, Y, 
RT, and the recently described PrimPol family.  Most polymerases of the A-, B-, 
and C- families have high fidelity and high processivity and are responsible for 
replication of chromosomal DNA2.  In humans, these families include all the 
polymerases necessary for replication of undamaged DNA: Pol α, δ, ε for the 
genomic DNA and Pol γ, the mitochondrial DNA polymerase10.  The X-family 
polymerases generally function in DNA repair pathways such as base excision 
repair (BER) in the case of Pol β, as well as non-homologous end joining (NHEJ) 
in the cases of Pol λ and μ11.  These polymerases resynthesize short stretches of 
DNA removed during repair11.  The Y-family polymerases are also important for 
DNA repair.  Y-family polymerases are known as translesion synthesis (TLS) 
polymerases because they bypass DNA lesions that stall replication forks, due to 
the inability of the high fidelity replicative polymerases to synthesize opposite the 
lesions12.  The RT sub-family, which includes Reverse Transcriptase from viruses 
as well as telomerase in eukaryotes, functions to synthesize DNA from RNA 
templates13, 14.  The final sub-family is the PrimPol family, characterized by 
having both primase and polymerase activity9, 15.   All polymerases are 
categorized into sub-families based on sequence homology.  Each sub-family is 
defined by a high degree of sequence similarity among its members, but 
homology between sub-families is exceptionally low given their shared 
chemistry16.  In fact, similarity between polymerase sub-families was too low for 
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useful sequence guided discovery of the more recently found polymerase sub-
families: X, Y, and PrimPol. The A, B, Y, and RT families share a similar fold 
while the X and C family polymerases appear to have evolved separately, having 
distinct folds7, 15.  However, despite the low sequence homology and unrelated 
tertiary structures, a highly similar domain organization is seen across the 
polymerase families7, 15. 
 The polymerase domain organization consists of three main subdomains; 
the palm, thumb, and finger 7 (Fig. 1).   The protein folds of these subdomains 
vary between families, with the A, B, Y, and RT families sharing a similar fold, 
while the X and PrimPol families both have unique folds.  Despite the different 
tertiary structures, the active site composition and subdomain configuration are 
highly conserved among all DNA polymerases, likely because the same chemical 
reaction is catalyzed by these enzymes (Fig. 1).  The thumb subdomain is 
involved in DNA binding, associates with the upstream DNA duplex, and 
contributes to processivity17.  This subdomain is present in all polymerase 
families except the PrimPols, which consequently have very low processivity15.  
The thumb subdomain is adjacent to the palm subdomain, which houses the 
three conserved active site carboxylates.  These acidic residues coordinate two 
Mg2+ ion cofactors in the active site that are required for polymerase catalysis.  
The active site is located in the palm subdomain at the interface of the palm and 
finger subdomains7.  The finger subdomain is located directly above the nascent 
base pair of the templating base and incoming dNTP7.  In high fidelity A-family 
polymerases, its positioning over the templating base allows the finger 
 5 
subdomain to sterically sense the conformation of the nascent base pair and to 
determine if the correct dNTP is bound18, 19.  This sensing is performed by an α-
helix termed the O-helix, which sterically prevents full closure of the finger 
subdomain onto mismatched template:dNTP base pairs, contributing to the 
extremely high fidelity of replication19.  Fidelity is further increased for some 
polymerases of the A, B, and C families by the presence of a 3´ to 5´ 
exonuclease activity, located either in a fourth structural domain or an associated 






Figure 1. Conserved architecture of polymerases   
The three polymerase domains are highlighted in color: Thumb in green, palm in 
red, and finger in blue.  Non-conserved elements are shown in grey, including the 
proofreading exonucleases of the A and B families.  Polymerases shown are Taq 
Klenow fragment (A-family, pdb code 3KTQ22), RB69 (B-family, pdb code 
4FK423), Pol β (X-family, pdb code 4PPX24), Pol η (Y-family, pdb code 3MR225), 
HIV-RT (RT-family, pdb code 1RTI26) and the Polymerase/Primase domain of 
pRN1 PrimPol (PrimPol-family, pdb code 1RNI15). 
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1.2. Polymerase active site and nucleotidyl transfer reaction  
The similar domain organization of polymerases reflects the structural 
characteristics necessary for their shared chemistry, incorporating free 
nucleotides (dNTP) into a growing DNA primer strand.  The protein fold of the 
palm domain varies between polymerase families (Fig. 1), however despite 
different folds, the active sites of all DNA polymerases that have been structurally 
characterized share a similar active site composition 15, 25, 27, 28.  The conserved 
active site core is composed of three carboxylates arranged in a triangle like 
pattern to coordinate two Mg2+ ion cofactors 15, 28.  The positive Mg2+ ions in turn 
bind the highly negative tri-phosphates of the incoming dNTP in polymerase-
DNA-dNTP ternary complex crystal structures (Fig. 2)29. 
Recently, using time resolved crystallography, the dynamics of 
polymerase catalysis was observed using Pol  by Nakamura et al (Fig. 2)27.  
They constructed a pre-reaction complex consisting of the polymerase complex 
with DNA, incoming nucleotide, and only one metal bound in the B-site.  For 
experimental reasons the metal in their structure was a Ca2+ ion instead of the 
Mg2+ ion which would be present in vivo.  The metal bound at the B-site 
coordinates the α, β, and γ phosphate oxygens25.  This ion is part of the 
Mg2+dATP complex in solution and thus is the first metal ion to bind with dNTP in 
the active site30, 31.  They termed this complex the Ground State (GS).  In the GS, 
both the dNTP and primer are bound but not aligned for catalysis, specifically the 
primer 3´-OH is too far from the α-phosphate, at over 4Å, to react27. The second 
Mg2+ ion, sometimes termed the catalytic Mg2+, next binds at the A-site to 
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coordinate the α-phosphate and the 3´-OH from the terminal base of the primer 
strand25, 29.  This state, with two Mg2+ ions bound, was termed the Reactant State 
(RS).  In the RS, the primer 3´-OH has shifted nearer the α-phosphate, to ~3.4Å, 
due to coordination with the A-site Mg2+ ion, and is aligned for nucleophilic attack 
(Fig. 2)25, 27, 32.  Once the polymerase transitioned fully from the GS to RS, the 
primer was deprotonated and underwent nucleophilic attack on the α-phosphate, 
forming the nascent bond between the primer and incoming nucleotide and 
cleaving the α- to β-phosphate bond27, 33.  This is believed to be an SN2 type 
reaction, having a penta-covalent α-phosphate transition state intermediate34, 35.  
The transition state is stabilized by interaction with both Mg2+ ions, which directly 






Figure 2. Polymerase Active Site and time resolved catalysis  
Time resolved structures of WT polymerase η catalyzing the addition of dATP 
onto a DNA primer solved by Nakamura et al (pdb codes: 4ECQ, 4ECS, and 
4ECV)27.  Protein residues are colored in salmon, the primer and incoming dATP 
nucleotide are colored in yellow, and the calcium and magnesium metal ions are 
colored in green and purple, respectively.   The Ground State (GS) is shown in 
the left panel prior to Mg2+ addition.  The Reactant State (RS) is shown in the 
middle panel and the Product State (PS) is shown in the right panel.  In the 
Product State a third Mg2+ ion was observed. 
 
 
Pre-steady state kinetic analysis of polymerase catalysis has been 
performed on a variety of DNA polymerases including Dpo437, Pol β38, 39, Pol η40, 
Pol I41, and Taq42 with a goal of defining the rate-limiting step in polymerase 
catalysis.  Based on early polymerase crystal structures, it was originally widely 
assumed that a large conformational change, closing the finger domain onto the 
dNTP bound palm domain prior to the reaction, was rate-limiting43.  However, 
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there is no direct data to support finger domain movement as the rate-limiting 
step.  More recent FRET and fluorescence based assays on Pol β, Klentaq1, and 
RB69 have measured the rate of finger domain movement as much faster than 
the rate of polymerization, proving it is not the rate-limiting step in catalysis38, 42, 44.  
Currently, it is believed that either the chemical step or a subtle active site 
conformational change immediately prior to, and possibly associated with, the 
chemical step is rate-limiting41, 44-47.  Unfortunately, due to the complexity of the 
polymerase active site there are limited means to assess conformational 
changes within the polymerase active site, such as altered enzymes or 
substrates. Consequently, the precise nature of the rate-limiting step has not yet 
been determined for polymerase catalysis46.  In lieu of precise experimental 
assignment of the rate-limiting step, quantum mechanical/molecular mechanics 
(QM/MM) simulations on polymerase β catalysis have indicated that 
deprotonation of the primer 3´-OH may be rate-limiting45.  It should be noted, 
however, that in my work steady state kinetic conditions are used.  Previous work 
on yeast Pol η have suggested that in steady state, single nucleotide insertion 
assays the disassociation of the polymerase from the DNA is rate-determining40.  
Chemical rates will be masked by this slow step in steady state conditions, 
unless enzyme or substrate perturbations significantly reduce these rates. 
The base responsible for deprotonation of the 3´-OH is not known for any 
polymerase and remains a critical question within the field.  Deprotonation by 
active site residues using a general-acid-base mechanism 48, 49 as well by solvent 
waters27, 45, 50, 51 have both been proposed.  QM/MM studies of 3´-OH 
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deprotonation on the Dpo4 and Pol β polymerase active sites have consistently 
favored solvent water for deprotonation45, 50, 51. The argument for solvent water 
deprotonation is further strengthened by a proposal by Tom Steitz that 
coordination of the 3´-OH to the Mg2+ ion, serving as a Lewis acid, lowers the 3´-
OH’s pKa dramatically, removing the requirement for a strong general base for 
deprotontation28.  Mg2+ ions serve as Lewis acids in a variety of other enzymatic 
reactions, lowering the pKa of catalytic groups to enable chemistries to occur that 
would otherwise require non-biological pH extremes52, 53.  The time-resolved 
crystallographic study of Pol  observed a water, which was termed the transient 
water, transiently associate with the 3´-OH and temporally correlate with product 
formation27, suggesting this water may accept the 3´-OH.  Nakamura and 
colleagues blocked binding of the transient water using an RNA terminated 
primer, which would occlude the transient water site with the 2´-OH, but did not 
observe significant activity loss27.  However, they hypothesized that the O2´ may 
relay the proton to bulk solvent instead; suggesting this route for the proton is still 
viable and requires additional interrogation.   
In a similar time-resolved experiment on the DNA polymerase Pol β, no 
transient water was seen during the early time points of the reaction, leading the 
authors to suggest one of the conserved aspartates deprotonate the 3´-OH33.  
However, the reaction occurred so rapidly no time points could be collected prior 
to product formation when deprotonation, and any transient water interactions, 
would occur.  Additionally, investigation of any of the three conserved acidic 
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residues is impossible with traditional mutagenesis methods used to identify 
general acids or bases, due to their role coordinating the Mg2+ ions. 
One other possible deprotonation candidate was identified in the Pol  
time-resolved structures: S11327.  S113 hydrogen bonds directly to the primer 3´-
OH in the GS.  The S113 position of Pol  is highly conserved across the 
polymerase superfamily as a serine in the Y-family, histidine in the A-family, and 
threonine in the B-family54.  Mutation of this site in E. coli Pol I resulted in 
reduced, but not totally eliminated, activity in vitro, suggesting this residue is not 
serving as the general base in polymerase catalysis55.  In Pol , an S113A 
mutation was shown in vitro to have only minimal activity loss, much less than 
observed for the Pol I mutation at this site27.  However, despite the high 
conservation of this site and the activity loss upon mutation no role has been 
described for this site. 
  In this work I combined mutational approaches with time-resolved 
crystallography of Pol η to directly observe the effect of site specific perturbations, 
of both protein residues and DNA nucleotides, on the polymerase catalysis 
dynamics.   This study focused on conclusively identifying and validating the 
moiety that accepts the 3´-OH proton upon deprotonation.   
 
1.3. The translesion synthesis (TLS) polymerase Pol η 
 Polymerase η is a member of the Y-family of DNA polymerases.  Pol η 
was discovered in patients presenting with Xeroderma Pigmentosum (XP) 
syndrome56, 57.  XP patients suffer from extreme sensitivity to any amount of 
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sunlight and increased incidence of keratoses and skin cancer that has been 
linked to deficient NER dependent repair of DNA damage, specifically UV light 
induced cyclobutane pyrimidine dimer (CPD) lesions58.  A subset of XP patients, 
however, had perfectly functional NER, and instead lacked functional Pol η.  
Consequently, Pol η was termed the Xeroderma Pigmentosum Variant (XPV) 
gene59, 60. Pol η deficient XPV cells have reduced survival upon UV treatment, 
indicating that Pol η is involved at the replication fork in bypassing CPD lesions58.  
Pol η, as well the other Y-family DNA polymerases, are known as translesion 
synthesis (TLS) polymerases, due to the intrinsic ability to synthesize past 
lesions present on the template strand61.  Each Y-family polymerase is 
specialized for a specific DNA lesion or subset of lesions12.  In vitro 
characterization of Pol η has confirmed Pol η’s role in bypass of CPD lesions25, 56, 
62.   
 For Pol η and other Y-family polymerases, access to the replication fork is 
a regulated event in the cell63.  Pol η fidelity is orders of magnitude lower than 
that of the canonical replicative polymerases such as Pol ε, and if allowed to 
replicate large sections of the genome would result in mutations64.  Instead, a 
mechanism termed polymerase switching is used when a replication fork 
encounters a lesion65, 66.  UV exposure activates the Rad6/18 dependent 
ubiquitylation of the PCNA.63.  Upon PCNA ubiquitination, Y-family polymerases 
are recruited to the fork67.  Once the appropriate TLS polymerase binds, in this 
case Pol η, TLS past the CPD lesion rescues the stalled fork25.  Y-family 
polymerases fortunately also have very low processivity, causing them to fall off 
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shortly after TLS of the lesion and to allow the high fidelity polymerase access to 
the fork25. 
 The structure of yeast Pol η has been solved by the Aggarwal group and 
human Pol  by the Yang group 25, 32, 68.  Pol η contains all the conserved 
polymerase subdomains: thumb, palm, and finger (Fig. 3A).  The 3´ to 5´ 
exonuclease domain seen in A- and B-family polymerases is not present in Pol η, 
which contributes Pol ’s lower in fidelity7, 21.  Instead Pol η, like all Y-family 
members, has a fourth subdomain termed the “little finger”69.  The little finger 
subdomain functions to bind the template strand during DNA synthesis past 
CPDs and other bulky lesions25.  The CPD lesion is large and distorts the B-form 
structure of the DNA double helix, causing misalignment of the active site 70.  
However, within the little finger subdomain of Pol η, a beta sheet makes 
extensive contacts to the phosphate backbone of the template to reinforce B-
form structure 25, 68.  Within the human Pol η structure, the DNA is bound on the 
opposite sides by the thumb and little finger subdomains, forming a molecular 
splint around the DNA that assists Pol η in positioning the lesion correctly in the 
active site25.  The Pol η active site itself is also specialized for TLS of large 
adducts.  Unlike the tight fitting active sites that ensure correct base pairing in the 
high fidelity polymerases, Pol η’s active site is very open, which also contributes 
to its lower fidelity25, 32.  The Pol η finger domain contains a large pocket above 
the templating base pair where adducts are accommodated during TLS25, 32 (Fig. 
3B).  This pocket is unique to Pol η, and is what allows Pol η to accommodate 







Figure 3. Polymerase  structure and bypass of a cisplatin lesion  
This figure is adapted from Zhao et al structures, pdb code 4DL4 32. A. Structure 
of Pol η bound to cisplatin damaged DNA in the active site.  The four domains of 
Y-family polymerases are highlighted with the thumb in green, palm in red, finger 
in blue and little finger in purple.  The DNA is shown in yellow (primer) and 
orange (template) with the incoming nucleotide in cyan and damaged guanines in 
stick representation.  B. The large active site of Pol η accommodates the cisplatin 
lesion during TLS.  The CPD-binding pocket, unique to Pol , is colored green.  




1.4. Platinum chemotherapeutics and cancer resistance to platinum 
compounds 
 The platinum drugs cisplatin, carboplatin, and oxaliplatin are used in the 
clinical treatment of approximately half of all cancer patients that receive 
chemotherapy 71. These platinum chemotherapeutics function mainly by binding 
to and damaging genomic DNA, primarily forming bifunctional intrastrand 
crosslinks72. Platinum-DNA lesions cannot be bypassed by high fidelity 
replicative polymerases, resulting in stalling of replication and transcription if left 
unrepaired, which induces apoptosis or lethal genomic instability 73, 74. Due to 
proliferation, cancer cells require much more frequent replication and 
transcription events, leading to greater susceptibility to platinum treatment 
compared to somatic cells. Many cancers, however, are either inherently 
resistant to the current platinum-based therapies or acquire resistance during 
treatment 75. This resistance limits the range of tumors that can be treated with 
these platinum compounds and hinders the widespread development of fully 
curative treatments. 
  The mechanisms cancer cells use to survive treatment with platinum 
compounds include decreased influx, increased sequestration by intracellular 
thiols, and increased efflux 76. These processes all serve to limit the amount of 
active platinum in the cell and thereby decrease the number of platinum-DNA 
lesions that form. Cancer cells can also become resistant to platinum compounds 
by increasing the rate at which they repair platinated DNA 77. Inhibition of DNA 
platination and removal of lesions prevent the stalling of polymerases that read 
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DNA and the consequent induction of apoptosis 78. Cancer cells also employ 
polymerases that can replicate through platinum lesions that persist or form 
during DNA replication, in order to prevent stalling 79. Translesion synthesis 
(TLS) is a mechanism naturally employed by cells to prevent common DNA 
damage from stalling replication forks and giving rise to high levels of apoptosis 
80, 81. For cisplatin resistance in particular, TLS appears to be critical. Cisplatin 
treatment efficacy is inversely correlated to expression levels of DNA polymerase 
 82. Pol η is specialized in bypass of UV light-induced cyclobutane pyrimidine 
dimer lesions 32. The enlarged active site and rigid DNA binding properties of Pol 
η allow it to incorporate nucleobases opposite large and helix-distorting, 
intrastrand crosslink adducts formed by cisplatin in a manner similar to the CPD 
83. The enlarged active site of the polymerase accommodates the crosslink and 
permits insertion of dC opposite the modified bases. After the first two insertion 
steps, however, Pol η is not proficient in extension past cisplatin lesions in vitro, 
and Pol ζ is postulated to extend the primer further until high-fidelity polymerases 
can rebind 32. siRNA knockdown of Pol η or Pol ζ hypersensitized cell cultures to 
cisplatin, confirming that TLS plays a role in cisplatin resistance in vitro 84. 
 To overcome the resistance that gives rise to decreased efficacy of 
platinum therapy, compounds with alternative, non-classical molecular structures 
are being investigated 85. Monofunctional platinum compounds differ from the 
clinically employed bifunctional species in that they form only one covalent bond 
to DNA 86. Phenanthriplatin, or cis-diamminephenanthridinechloroplatinum(II), is 
a novel monofunctional platinum agent that has displayed very promising 
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anticancer activity (Fig. 4) 87. Phenanthriplatin was identified as a result of a 
systematic variation of the N-heterocyclic ligand, informed by the crystal structure 
of RNA polymerase II stalled at a pyriplatin-platination site 88. Phenanthriplatin 
maintains a spectrum of activity that is distinct from that of any other platinum 
agent tested in the NCI60 human tumor cell line anticancer drug screen and is 7 
to 40 times more potent than cisplatin. The complex interacts covalently with 
DNA, presumably at the nucleophilic N7 position of guanine, and inhibits 
transcription by RNA polymerase II 87, 89, 90. Phenanthriplatin contains a center of 
chirality and can therefore form diastereomeric adducts with DNA. Small 
molecule studies indicate that rotation about the bond between the platinum 
center and the phenanthridine ligand or the guanine (Pt–NP and Pt–NG, 
respectively) is facile but that one diastereomeric form is preferred over the other 
(Fig. 4B) 91.  Monofunctional platinum adducts and phenanthriplatin in particular 
represent a promising new design for next generation chemotherapies but further 




A. The cisplatin compound binds two guanines, forming a bulky and rigid 
bifunctional adduct.  B. Phenanthriplatin binds only a single guanine to form a 
more flexible monofunctional adduct. The carbon atoms of the phenanthridine 
ligand are shown in magenta. The major degrees of freedom available to the 
flexible phenanthriplatin lesion are demonstrated. 
Figure 4. Chemical structures of cisplatin and phenanthriplatin and 
depictions of cisplatin and phenanthriplatin damaged DNA 
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1.5. Objectives of thesis research and significance of findings 
 The first objective of my thesis research was to characterize the 
mechanism of Pol η catalysis at the molecular level, specifically concerning 
alignment and deprotonation of the primer.  Recently a new technique, time 
resolved crystallography has been developed for use with Pol η27.  This 
technique has enabled me to visualize atomic details of the active site in a time-
lapse series during Pol η catalysis.  Previous studies have implicated a number 
of moieties in deprotonating the primer 3´-OH, including the S113 residue and 
the transient water27, 48-51.  My work identifies a key structural transition from a 
ground state conformation to a reactant state conformation that is critical for 
efficient deprotonation and catalysis, and also identifies the S113 residue as the 
mediator of this transition.  Additionally, I collected data that demonstrated that 
the transient water was not solely responsible for primer deprotonation, and 
suggests that the general base can be varied in the polymerase catalysis 
mechanism.  Given the highly conserved nature of polymerase active sites, these 
finding likely also shed light onto the mechanism used by most, if not all, 
members of the polymerase superfamily. 
 The second objective of this thesis research was characterization of Pol η 
as a target for inhibition.  Due to Pol η’s proven role as a resistance gene against 
chemotherapy treatment in cancers, Pol η inhibition represents a promising 
therapeutic goal82.  This research was approached from two fronts: identification 
of small molecule binding sites for rational design of conventional inhibitory 
compounds, and development of platinum chemotherapeutics that present a 
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greater impediment to Pol η TLS.  In this work I identified a novel druggable 
pocket in the Pol η thumb domain and verified the inhibitory potential of this 
binding site biochemically32.  Further, I observed binding of dNMPNPPs at the 
inhibitory site in crystal structures of Pol η and confirmed the location through 
directed mutagenesis32.  Though no compounds have been found yet to target 
this site, such drugs have to potential to increase chemotherapeutic efficacy 
through adjuvant therapy. 
Platinum-based chemotherapies are among the most successful anti-
cancer treatments available currently, but current platinum chemotherapeutics 
are only effective against some cancer types and are limited by acquired 
resistance in cancers74, 92. The platinum-based derivative, phenanthriplatin, 
shows improved cytotoxicity over traditional chemotherapeutics in a variety of 
cancer cell lines87.  Here I present an investigation of the effect of 
phenanthriplatin adducts on replication and the ability of DNA polymerases to 
replicate past a site-specific phenanthriplatin lesion.  Among a panel of DNA 
polymerases, Pol η was the only one able to bypass the phenanthriplatin lesion, 
although it does so with a very low efficiency. Kinetic studies of the different 
steps in TLS past phenanthriplatin lesions were carried out, and the results are 
interpreted in light of the crystal structures of the polymerase stalled at the first 
two steps of TLS. These structural studies reveal the nature of the interaction of 
Pol η with phenanthriplatin platinated DNA.  They also elucidate the mechanism 
by which the structure of phenanthriplatin inhibits TLS in a manner distinct from, 
and more potent than, current platinum chemotherapeutics.  This work 
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demonstrates the therapeutic potential of monofunctional platinum 
chemotherapeutics such as phenanthriplatin in overcoming known cancer 






2.1. Pol η cloning and expression in E. coli 
The gene encoding the human Pol η 1-432aa fragment was codon 
optimized for expression in E. coli and ordered from Genescript.  The coding 
region was cloned into a modified pET28p plasmid using NdeI and XhoI 
restriction enzymes, leaving the N-terminal 6xHis tag and protease cleavage site.  
The pET28p plasmid is a modified version of the pET28a plasmid in which the n-
terminal thrombin cleavage site is substituted for a PreScission protease site93.  
The cloned Pol η 1-432aa construct was transformed into BL21 (DE3) cells for 
expression.  In LB broth the expression strain was grown at 37˚C to an OD~0.6-
0.8 then cooled briefly on ice to ~16˚C.  Expression was initiated with addition of 
0.4 mM IPTG and incubated at 16˚C over night (~20 hrs) after which cells were 
harvested, frozen in liquid nitrogen, and stored at -80˚C until purification. 
 
2.2. Purification of Polymerase η protein 
Frozen Pol η 1-432aa expression cell pellets were thawed and suspended 
in cold lysis buffer (20 mM Tris pH 7.5, 1000 mM NaCl, 10 mM imidazole, 3 mM 
BME, Sigma protease inhibitor tablet).  Cell disruption was performed with an 
Emulsiflex system and the lysate was clarified by ultracentrifugation at 35,000 
rpm for 35 minutes followed by 0.22 μm filtration.  The lysate was loaded onto a 
5ml nickel column equilibrated in NickelA buffer (20 mM Tris pH 7.5, 1000 mM 
NaCl, 15 mM imidazole, 3 mM BME, 5% glycerol), then washed with 60 mM 
imidazole to remove non-specific binding proteins, and finally eluted with 300 mM 
imidazole.  The eluted protein was buffer exchanged with a NAP-25 column into 
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PreScission buffer (20 mM Hepes/NaOH pH 7.0, 500 mM KCl, 3 mM DTT, 0.1 
mM EDTA, 10% glycerol), cleaved at 4°C overnight with 1:100 ratio PreScission 
Protease, and then again buffer exchanged with a NAP-25 column into MonoS-C 
buffer (20 mM MES pH 6.0, 250 mM KCl, 3 mM DTT, 0.1 mM EDTA, 10% 
glycerol).  The protein was next loaded onto a 5 ml MonoS column pre-
equilibrated with MonoS-C buffer and eluted by gradient (up to 1 M KCl in 100 
ml).  The eluted protein was pooled, concentrated, and run on a Superdex75 
column pre-equilibrated in Sup75 buffer (20 mM Tris pH 7.5, 450 mM KCl, 3 mM 
DTT).  The purified Pol η eluted as a monomer at ~10.5ml, while a small 
aggregate peak is present at ~8ml elution volume.  The resulting monomer peak 
fractions are >98% pure Pol η protein.  An identical procedure was used for all 
Pol η mutants. 
 
2.3. DNA Oligonucleotides 
Oligonucleotides were obtained from Integrated DNA Technologies (IDT), 
the FDA Facility for Biotechnology Resources (FBR), or Sigma Aldrich.  The 
oligonucleotide sequences used for steady state kinetic measurements and run-
off polymerization assays are shown in their respective figures or in Table 2.  
Oligonucleotides used for crystallization are as follows: dA terminated primer 
template duplex (5´- CATTTTGACGCT -3´ and 5´- AGCGTCAA -3´), rA 
terminated primer template duplex (5´- CATTTTGACGCT -3´ and 5´- 
AGCGTCArA -3´), dT terminated primer template duplex (5´- CATTATGACGCT -
3´ and 5´-AGCGTCAT -3´), 2´-fluoro-dA terminated primer template duplex (5´- 
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CATTTTGACGCT -3´ and 5´- AGCGTCAAF -3´), Insertion complex against 
phenanthriplatin (5´- CATGCTCACACT -3´ and 5´- AGTGTGAG -3´), +1 
extension complex against phenanthriplatin (5´- CATCGTCACACT -3´ and 5´- 
AGTGTGAC -3´).  A bold G denotes the site of phenanthriplatin damage.  
Phenanthriplatin damaged DNA oligonucleotides were provided by our 
collaborators in the Stephen Lippard Lab at MIT. 
 
2.4. Steady state primer extension assay 
Steady state kinetic parameters KM and Kcat were measured using the 
template/primer pairs shown in the respective figures or tables.  The reaction 
mixture contained 2.5 or 5 nM Pol η, 0-60 μM dNTP, 5 μM 5´ 6-FAM labeled 
primer and template (1:1000 or greater enzyme to substrate ratio), 40 mM Tris 
pH 7.5, 5 mM MgCl2, 100 mM KCl, 10 mM Dithiothreitol, 0.1 mg/ml Bovine 
Serum Albumin, 5% glycerol.  Reactions were initiated by addition of the dNTP 
corresponding to the next incorporation only (i.e. if template position is T then 
dATP is added) and 5 mM MgCl2 followed by incubation at room temperature for 
5 minutes.  These conditions allow extension of primers only by 1 base but 
multiple turnovers for each enzyme.  The reactions were quenched with an equal 
volume of formamide, 10 mM NaOH, and xylene cyanol.  After heating the 
samples at 90°C for 3 minutes and rapid cooling on ice the samples resolved on 
20% poly-acrylamide gels containing 7.5M urea at 300V.  The gels were pre-run 
20 minutes to increase the running temp to >30˚C, loaded with 4ul sample, and 
run until the Bromophenol Blue dye was nearly completely run out of the gel.  
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The gels were visualized using a Typhoon Trio (GE Healthcare), quantified using 
ImageQuantTL (GE Healthcare) software, and curve fitting was performed using 
Prism 5 (Graphpad) software.  Representative gel and quantification is shown in 
figure 5 to demonstrate the separation of substrate (primer) and product 
(extended primer) achieved.  Reported errors are calculated standard error of the 
mean (SEM) from triplicate experiments and best-fit error values were calculated 
with a least squares non-linear regression analysis in Prism 5(Graphpad).  All 
kinetics data were fit to the Michaelis-Menten equation, Y=Vmax*X/(Km+X), 
where Y is the extension rate, Vmax is the extension rate at infinite incoming 
nucleotide concentration, X is the concentration of incoming nucleotide, and Km 
is the Michaelis-Menten constant.  The inhibition activity seen in figure 6 was fit 
with a one phase decay equation, Y=(Y0 - Ymin)*exp(-K*X) + Ymin, where Y is 
extension rate, Y0 is the extension rate at the highest measured value, Ymin is 
the asymptotic value of Y at infinite incoming nucleotide concentration, K is the 






Figure 5. Representative steady state kinetics measurement 
Reactions of wild type Pol  extending a dT terminated primers were run into a 
20% TBE-UREA gel.  Product formation was quantified with ImageQuantTL and 
fit to the Michaelis-Menten equation, Y=Vmax*X/(Km+X), to determine the kinetic 







2.5. Run-off polymerization assay   
Pol η 1-432aa was cloned, expressed, and purified as described in section 
2.2.  Pol ν and Pol ζ were generously supplied by Young-Sam Lee and cloned, 
expressed, and purified as described previously 94.  Klenow fragment was 
obtained from New England Biolabs (Product# M0210S).  Pol κ was obtained 
from Enzymax (cat# 27).   
 The template/primer pairs used are shown in figure 17.    The reaction 
mixture contained 0-50 nM Polymerase, 25 μM each dNTP, 100 nM 5´ 6-FAM 
labeled primer and template, 40 mM Tris pH 7.5, 5 mM MgCl2, 100 mM KCl, 10 
mM Dithiothreitol, 0.1 mg/ml Bovine Serum Albumin, 5% glycerol.  Reactions 
were initiated by addition of all four dNTP (0.25 mM each) and 5 mM MgCl2, 
incubated at 30°C for 5 minutes (10minutes for Pol ζ), and quenched with an 
equal volume of formamide, 10 mM NaOH, and xylene cyanol.  After heating 
samples at 90°C for 3 minutes and rapid cooling on ice, the primers were 
resolved on 20% poly-acrylamide (15% for Pol ζ) gels containing 7.5M urea at 
300V after a 20 minute pre-run, visualized using a Typhoon Trio (GE Healthcare), 
quantified using ImageQuantTL (GE Healthcare) software. 
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2.6. Nucleotide preference (fidelity) assay 
Nucleotide preference was measured using the template/primer pairs 
shown in figure 18.  The reaction mixture contained 2 nM Pol η, 25 μM dNTP, 5 
μM 5´ 6-FAM labeled primer and template, 40 mM Tris pH 7.5, 5 mM MgCl2, 100 
mM KCl, 10 mM Dithiothreitol, 0.1 mg/ml Bovine Serum Albumin, 5% glycerol.  
Reactions were initiated by addition 0.25 mM of the indicated dNTP and 5 mM 
MgCl2, incubated at room temperature for 5 minutes, and quenched with an 
equal volume of formamide, 10 mM NaOH, and xylene cyanol.  After heating at 
90°C for 3 minutes and rapid cooling on ice the primers were resolved on 20% 
poly-acrylamide gels containing 7.5M urea at 300V after a 20 minute pre-run, 
visualized using a Typhoon Trio (GE Healthcare), and quantified using 
ImageQuantTL (GE Healthcare) software. 
 
2.7. Crystallization and Data Collection 
For crystallization, purified Pol η was mixed in a 1:1.09 molar ratio with 
DNA and either 5 mM MgCl2 (static structures) or 1:1 CaCl2 and 1:1.5 dATP (time 
resolved structures) followed by incubation on ice to form a binary complex.  
DNA oligonucleotides used are indicated for each experiment.  After three-fold 
dilution to reduce salt concentration to 150 mM KCl the complex is concentrated 
to at least 3.5 mg/ml and the appropriate dNMPNPP (static structures) or dATP 
(time resolved structures) was added to form the ternary complex.  Crystals were 
obtained using the hanging drop vapor diffusion method over a reservoir 
containing 0.1 M MES pH 6.0, 15-20% PEG 2000-MME.  Microseeding was used 
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when consistent crystal sizes were difficult to obtain with simple vapor diffusion.  
For static structures of the enzyme-substrate complex, crystals were soaked 
briefly in 0.1 M MES pH 6.0, 20% PEG 2000-MME, and 20% glycerol for cryo 
protection then flash frozen in liquid nitrogen.  For time resolved, reaction 
progress structures, crystals were soaked 30 minutes in 20% PEG 200-MME, 0.1 
M Mes/KOH pH 7.0, 1 mM DTT, 5 μM dATP then transferred to 20% PEG 2K-
MME, 0.1 M Mes/KOH pH 7.0, 1 mM DTT, 1 mM MgCl2 for the indicated time.  
The crystals were then briefly transferred through 20% PEG 2K-MME, 0.1 M 
Mes/KOH pH 7.0, 1 mM DTT, 1 mM MgCl2, 20% glycerol for cryo protection prior 
to freezing in liquid nitrogen.  Diffraction data were collected at 100K on the 
22BM beamline at the Advanced Photon Source (APS). 
 
2.8. Macromolecular Structure Determination 
Diffraction data were processed with HKL2000 or XDS and converted to 
structure factors by TRUNCATE 95-98.  All datasets were in the P61 space group 
and isomorphic with previously solved Pol η structures (PDB code 3MR2 or 
4ECQ), which were used to obtain phases, using simple rigid-body refinement.  
Models were built in COOT and refined in PHENIX 99, 100. All structural figures 
were rendered in PyMol 101.  Data collection and refinement statistics are shown 





3. Inhibition of DNA Polymerase η by high nucleotide 
concentration and a potential inhibitor binding pocket 
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3.1. Polymerase η has reduced activity at high incoming nucleotide 
concentrations 
 Once I had obtained sufficiently pure Pol η protein, I set out to measure 
the steady state kinetic constants governing its polymerization activity.  A 
previous member of our lab had noticed inconsistent measurements for Pol  at 
high dNTP concentrations.  I measured Pol  steady state primer extension, and 
visualized extended primers by gel electrophoresis.   Surprisingly, when I 
measured Pol ’s kinetic profile, focusing on high dNTP conditions, I found that 
Pol ’s kinetic profile is different from other polymerases I have tested.  The 
polymerization activity increases with increasing incoming nucleotide (dNTP) 
concentration until ~80 μM (Fig. 6).  However, dNTP concentrations beyond 80 
μM have an inhibitory effect on overall Pol η activity.  Fitting of the low dNTP 
concentration phase and high dNTP concentration phase separately, with a 
Michaelis-Menten and one phase decay, respectively, gives an estimate of the 
inhibition as roughly 40 percent loss in activity at dNTP concentrations > 0.5 mM 






Figure 6. Inhibition of Pol η by high dATP concentration   
Steady state extension activity at dATP concentrations greater than ~500 μM Pol 
η is inhibited (solid blue).  The expected activity of Pol η in the absence of dATP 
dependent inhibition is shown with a dashed blue line.  Data points at low dATP 
concentration were fit with the standard Michaelis-Menten equation, see methods, 
and used to extrapolate the expected activity in absence of inhibition.  Data 
points above 50 μM dATP were fit with a one phase decay equation, see 
methods.  Inset shows the separation of the substrate (primer) and product 




The deviation of Pol η kinetics from a simple Michaelis-Menten kinetic 
model demonstrated that either dNTP could bind Pol η at multiple sites or bind at 
the active site in multiple orientations.  The high conservation of active site 
configuration across all polymerase families suggests multiple binding motifs 
within a polymerase active site are not likely.  The most likely explanation is that 
a second, lower affinity binding site for dNTP exists.  Inhibition by dNTP binding 
at this site is not competitive, as saturation fails to eliminate activity, but is 
instead a case of non-competitive inhibition, explaining the reduced, but non-zero, 
activity at saturation. 
 
3.2. A Secondary nucleotide binding site in the Pol η thumb domain 
 In searching for a secondary binding site for dNTP I re-examined 
previously solved Pol η ternary complex crystal structures to identify binding 
pockets32.  Each structure had a small, unexplained density in an exposed 
hydrophobic pocket between the thumb domain and the bound DNA (Fig. 7A).  
All previous structures had been solved from crystals grown in buffers containing 
1 mM dNMPNPP, a non-hydrolysable nucleotide analog, and the density could 
be explained by modeling the base moiety of the dNMPNPP used in 
crystallization.  The ribose and phosphate moieties were disordered and not 
observed.  The modeled dNMPNPP was stabilized by π-π interactions with 
tryptophan 297 residue within the thumb domain (Fig. 7A).  I produced a W297A 
mutant to remove the proposed interaction.  The mutation significantly reduced 
kcat, likely due to destabilization of the thumb domain and DNA binding, but also 
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eliminated the inhibitory effect at high dNTP concentrations, returning the kinetic 
profile a normal Michaelis-Menten kinetics (Fig. 7B).  Loss of the inhibitory 
activity identifies the binding site near W297 as being responsible for inhibition at 
high dATP concentrations.  Physical identification of the binding site confirms that 
the inhibition is noncompetitive because the inhibitor binding site is non-





Figure 7. The inhibitory binding site is located on the thumb domain 
between Pol η and the upstream DNA 
A. dATP bound between W297 in the thumb domain (shown in green) and the 
upstream DNA duplex (shown in yellow and orange).  The structure is masked 
with an omit map of the dATP shown in blue at 2σ.  B. Steady state kinetics of 
W297A mutant Pol η is not inhibited by high dATP concentrations, confirming 
dATP binding at this site is responsible for the observed inhibition of WT Pol .  
These figures are adapted from my published work32. 
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3.3. The Secondary nucleotide binding site is a target for potential 
inhibitor development 
 Despite Pol ’s role in cancer resistance to chemotherapy no 
pharmaceuticals are currently available that inhibit Pol , though there is 
significant interest in inhibitor development.  The demonstrated inhibitory 
incoming nucleotide binding pocket is a promising target for rational drug design.  
The structure of an incoming nucleotide offers a starting point for design of 
inhibitor candidates.  As only the base portion of the nucleotide is sufficiently 
ordered to be visible in the structures, compounds with large aromatic rings offer 
the most promise.  I have screened a number of aromatic compounds available 
to my lab but, aside from dATP, none have been effective (Table 1).  A wider 
library of aromatic compounds will be needed to identify specific higher affinity 
inhibitors.  Among polymerases, compounds capable of binding this site will likely 
be quite specific for Pol η, as sequence comparison with other Y-family DNA 








Y-family polymerases in human (hs) and yeast (ys) aligned around the helix 
containing W297A.  W297A and the corresponding positions from other 
polymerases are shown in red.  Conserved hydrophobic residues that form the 
pocket are shown highlighted in yellow, non-hydrophobic conserved residues in 
cyan.  This figure is reprinted from my published work32. 
 





4. The active site S113 residue facilitates alignment of the DNA 
primer end for catalysis  
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4.1. Sequence conservation within Polymerase η active site 
 The active site of Y-family polymerases (residues contacting the primer 
terminus, magnesium ions, and incoming nucleotide) resides at the interface of 
the palm and finger domains.   Both domains have a number of highly conserved 
residues whose functions have been elucidated with structures of a variety of 
polymerases102.  The palm domain contains the three critical acidic residues that 
coordinate two magnesium ions required for catalysis25.  The magnesium ions 
are also coordinated by the triphosphate of the incoming dNTP and balance its 
large negative charge.  The finger domain also interacts with the incoming 
nucleotide with conserved polar and aromatic residues that stabilize its binding in 
the correct orientation for catalysis102.   
 Of the conserved residues near the active site nearly all have been 
assigned roles as either important or required for stabilizing the protein fold, 
structural integrity, DNA binding, or polymerase reaction activity102.  However, the 
polymerase tertiary structures used in assigning these roles were obtained using 
modified substrates or polymerase mutants to inhibit activity to gain homogeneity 
in sample preparation and facilitate crystallization.  The most common 
modification is to remove the 3´-OH from the terminal base of the primer23, 103, 104.  
This hydroxyl, once deprotonated, acts as the nucleophile during catalysis and its 
removal completely inactivates the polymerase/DNA complex.  The lack of this 
important component has hindered assignment of catalytic roles to some active 
site residues, such as the S113 position in human Pol η.   
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Within the Pol η active site S113 is positioned very near the catalytic 3´-
OH of the primer strand and E116, an acidic residue that coordinates the A-site 
magnesium ion (Fig. 9B).  S113 is highly conserved within the Y-family 
polymerase family102 (Fig. 9A).  The analogous positions in the A- and B-family 
polymerases are strictly conserved, though the amino acid conserved within each 
polymerase family is different, histidine and threonine, respectively (Fig. 9B-D).  
Conservation of this position suggests an important catalytic role but thus far 
none has been demonstrated. 




Figure 9. Alignment of active site residues within the polymerase sequence 
motif III 
A. A-family alignment includes: Bacteriophage T7 Pol (DPOL_BPT7, P00581), T. 
thermophiles Pol I (DPO1F_THETH, P30313), B. caldotenax Pol I 
(DPO1_BACCA, Q04957), R. Helvetica Pol I (DPO1_RICHE, Q9RLB6), H. 
sapiens Pol ν (DPOLN_HUMAN, Q7Z5Q5), H. sapiens Pol G1 (DPOG1_HUMAN, 
P54098), H. sapiens Pol Q (DPOLQ_HUMAN, O75417).  B-family alignment 
includes: E. coli Pol II (DPO2_ECOLI, P21189), B. taurus Pol δ (DPOD1_BOVIN, 
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P28339), A. thaliana Pol δ (DPOD1_ARATH, Q9LVN7), H. sapiens Pol ε 
(DPOE1_HUMAN, Q07864), S. cerevisiae Pol ε (DPOE_YEAST, P21951), S. 
pombe Pol ζ (DPOZ_SCHPO, Q9P6L6), D. melanogaster Pol α 
(DPOLA_DROME, P26019). Y-family alignment includes: H. sapiens Pol  
(POLH_HUMAN, Q9Y253), S. cerevisiae Pol  (POLH_YEAST, Q04049), H. 
sapiens Pol ι (POLI_HUMAN, Q9UNA4), H. sapiens Pol κ (POLK_HUMAN, 
Q9UBT6), S. cerevisiae Rev1 (REV1_YEAST, P12689), E. coli Dpo4 
(DPO4_ECOLI, Q47155), S. solfataricus Dpo4 (DPO4_SULSF, P96022).  The 
structurally conserved S113 position in human Pol  is highlighted in each 
alignment.  The conserved secondary structures are also shown above the 
sequences.  Alignment was performed with the Clustal Ω program105.  B. Active 
site of Y-family DNA Polymerase  demonstrating the structural position of the 
S113 residue (pdb code, 3MR2)25.  C. Active site of A-family T7 DNA polymerase 
demonstrating the similarity of the H653 position to that of the S113 residue of 
the Y-family DNA polymerase , however H653 is pointing in away from the 
active site, likely due to the lack of a primer 3´-OH used in crystallization(pdb 
code, 1T8E)103.  D. Active site of B-family DNA polymerase II demonstrating the 
structural similarity of the T546 position to that of the S113 residue of the Y-




4.2. Mutation of Polymerase η S113 reduces incorporation rate 
 Due to S113’s proximity to the primer 3´-OH, I hypothesized that S113 is a 
player in the deprotonation process, which is still not understood for the 
polymerase reaction.  An S113A mutant has made previously27 and I used this 
mutant to assess roles that S113 may play in catalysis.  The serine to alanine 
mutation was chosen to remove the hydrogen bond and acid/base chemistry 
competent hydroxyl, while maintaining the general size and structure of the 
residue27.  The steady state kinetic parameters of single nucleotide incorporation 
were measured for the mutant extending a dA terminated primer .  The S113A 
mutant has an 8- fold higher KM and 5-fold lower catalytic activity than WT (Fig. 
10A and Table 2).  The S113A mutant activity has been measured previously on 
dA terminated primers by Nakamura et al27.  Their measurement of the S113A 
mutant’s activity was considerably higher, having 95% of the kcat value seen for 
the WT.  However, I believe their published measurements are inaccurate as I 
have not been able to reproduce this high activity.  Using new protein and 
reagents or using samples of protein and reagents obtained from the original 
authors, the S113A mutant activity is consistently ~5 fold lower than WT, having 
a kcat of only 13 min
-1.  If S113 were the general base responsible for primer 
deprotonation the catalysis would be eliminated. Despite the lower activity level 
than previously reported, there remains observable catalytic activity for the 
S113A mutant which demonstrates that S113 is not essential for extracting the 
proton from the primer 3´-OH, consistent with the conclusions drawn by 
Nakamura et al27.  However, loss of the S113 hydroxyl in the mutant does lead to 
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a substantial loss of activity indicating an important role, either in stabilizing the 
fold or in a specific hydrogen bond interaction with substrates or other active site 
components.   
To investigate which roles S113 may be playing, the structure of the 
S113A mutant Pol η bound to a DNA template primer duplex, Mg2+ and a non-
hydrolysable dAMPNPP was solved to 2.27Å (Fig. 10B).  The mutant showed no 
gross defect in folding with an RMSD of only 0.218 Å over 399 pairs of Cα atoms 
when superimposed with the WT structure 25. The alanine adopts a phi/psi angles 
and sidechain positioning nearly identical to that of the WT serine.  Locally, the 
active site fold of the mutant is also unchanged, coordinating both Mg2+ ions and 
positioning the primer 3´-OH optimally (Fig. 10B).  The static molecular structure 
alone, showing no significant perturbation, was not able to explain the large loss 
in activity observed in solution. 





Figure 10. Pol η S113A mutant has reduced activity 
A. Steady state kinetic profiles of WT and S113A mutant Pol  extending primers 
terminating in dA.  Kinetic parameters for each profile are listed in table 2.  B. 
Structural alignment of WT and S113A active sites.  Both WT (pdb code 3MR225, 
shown in lightblue sticks) and S113A mutant (shown in colored sticks, yellow 
incoming dAMPNPP, salmon protein residues, and grey primer) are bound to a 






Table 2. Steady state kinetic parameters of WT and S113A Pol η extension 




4.3. Non-productive conformations of the primer 3´ terminal dT observed 
in the S113A mutant Polymerase η active site 
 Static crystal structures only observe conformations that are present at 
equilibrium within the crystallization drop.  To observe changes in transient 
conformations and structural transitions undergone during Pol η catalysis due to 
S113A mutation, I employed time resolved crystallography with S113A mutant 
Pol η and primers terminated in either dT or dA.  Briefly, crystals of the S113A 
mutant Pol η were grown in complex with a primer/template duplex in the 
presence of equimolar calcium and excess dATP.  Once fully grown the crystals 
were activated by transition to a magnesium containing buffer and frozen in liquid 
nitrogen at a number of reaction time points. 
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 In contrast to the static structure, the S113A active site bound DNA with a 
dT terminated primer is not configured in a single, ground state (GS) like state in 
the time resolved structures at the 0 sec time point, prior to activation by Mg2+ 
addition (Fig. 11A).  At 0 sec of the WT time course, only a single Ca2+ ion is 
bound in the B-site and the terminal dT of the primer strand is found uniformly in 
the GS position.  In contrast, the ground state of the S113A mutant displayed at 
least two conformations27, one conformation corresponds to the standard GS, 
while in the other conformation the terminal dT of the primer is shifted out of the 
active site and adopting a non-productive conformation (Fig. 11A).  The non-
productive conformation of the primer terminal base is no longer base stacked 
with the neighboring base in the primer stand, though it is still able to hydrogen 
bond with the templating base.  The incoming nucleotide binding site is in steric 
conflict with the non-productive primer conformation resulting in reduced 
occupancy of the dAMPNPP and active site Ca2+ ion in the pre-reaction, 0 sec 
structure.  Alternate conformations are also observed for the conserved aspartate 
residues responsible for Mg2+ binding.   
 The non-productive conformation of the primer terminus persists after 
activation of the polymerase by Mg2+ addition.  Similar to WT Pol η, Mg2+ binding 
is observed at the metal ion A-site immediately after soaking the crystals in a 
buffer containing Mg2+, though the A-site occupancy is only 30%. Despite 
observed Mg2+ binding in structures solved at time points up to 480 sec no bond 
formation is detectable, from either of the two primer conformations (Fig. 11A).  
The subpopulation of complexes with non-productive primer conformations 
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cannot react due to the lack of bound dATP.  However, dATP is bound within the 
subpopulation of Pol η complexes (50%) with the primer terminus in the normal 
GS position, but even this subpopulation shows no activity suggesting the S113A 
mutation is defective for more than just orienting the primer prior to Mg2+ binding. 
 The steric clash between the incoming nucleotide and the non-productive 
primer conformation predicts that the conformation of the active site can be 
modulated by concentration of incoming nucleotide.  The static structure of Pol η 
bound to the dT terminated primer was solved in 5 mM Mg2+ and 100 µM 
dAMPNPP, which more closely mimics the concentrations in vivo and the 
solution kinetic measurements.  As shown in figure 10B, at 1 mM dAMPNPP the 
S113A active site bound the incoming dAMPNPP and Mg2+ ions indistinguishably 
from WT.  However, at the 100 µM concentration the occupancy of dAMPNPP in 
the drops significantly to 0.3 indicating that the mutant active site binds incoming 
nucleotide much weaker than the WT.  The major conformation the primer 
terminal dT is in the non-productive conformation, the conserved active site 
acidic residues are shifted out of the active site, and there is reduced occupancy 
for the Mg2+ bound at both sites (Fig. 11B).  The WT Pol η complex structure 
solved in identical, in vivo mimic conditions retained full dAMPNPP binding and a 
well organized, catalytically competent active site, demonstrating that the S113A 
mutation reduces the affinity for the incoming nucleotide when the primer is not 
stabilized in the GS position by a hydrogen bond with the S113 hydroxyl.  The 
loss of the S113 to 3´-OH interaction likely contributes to the ~8 fold increase in 
KM values seen for the S113A mutant compared to WT (Fig. 10A).  
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Figure 11. Non-productive conformation of the primer terminal dT base in 
the S113A Pol η active site 
A. 2Fo-Fc (1σ) and Fo-Fc (3σ) maps calculated omitting the non-productive 
primer conformation superimposed onto the 0 sec (left) and 480 sec (right) 
structures of S113A Pol η - dT terminated primer complex.  The non-productive 
primer and active site residue conformations are shown in magenta.  B. Static 
structures of WT (shown in semi-transparent blue) and the major conformation of 
S113A (shown in grey and salmon) Pol  under physiological concentrations of 
incoming nucleotide, 100 µM dAMPNPP. 2Fo-Fc density of the S113A 




4.4. Reaction competent alignment of the primer is influenced by base 
stacking of the primer 3´ terminal base 
 To investigate roles of S113 in DNA synthesis by Pol η, time resolved 
structures of S113A mutant Pol η extending a primer terminated with dA were 
solved.  The adenine base, which is known for the best stacking potential104, at 
the primer terminus almost completely eliminates the non-productive primer 
conformation, and the canonical GS conformation is observed at 0 sec (Fig. 12).  
This is likely due to the increased base stacking between the primer strand and 
the incoming nucleotide that stabilizes the 3’ end of the primer strand106.  
Specifically, the primer terminal adenine base stacks with the upstream primer 
base prior to dNTP or Mg2+ binding, stabilizing the productive conformation 
sufficiently to eliminate non-productive conformation observed with pyrimidine 
terminated primers (Fig. 11), even without the S113 to 3´-OH interaction.  
Productive binding of the adenine terminated primer in turn allows for efficient 
dNTP and Mg2+ binding, as seen in time courses with S113A mutant on dA 
terminate primers (Fig. 12).  Base stacking of primer terminal pyrimidine bases is 
not sufficiently strong to stabilize the productive primer conformation in the 
absence of the S113 to 3´-OH interaction. 
Proper binding and alignment of the primer terminus is thus influenced by 
both the base stacking potential and hydrogen bonding of the 3´-OH with the 
active site S113 residue.  S113 stabilization appears to be more important for 
extension of pyrimidines than purines, due to their weak base stacking potential, 
and allows for more sequence-independent extension rate.  The more ordered 
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dA terminated primer can be extended by the S113A polymerase in crystallo.  
Upon activation with Mg2+ exposure, the metal A-site is occupied and the 
reaction proceeds (Fig. 12).  This is in agreement with solution kinetics showing 
the S113A mutant remains catalytically active on dA terminated primers.  On dT 
terminated primers there is no detectable reaction occurring within the crystal, 
perhaps due to the decreased stability of the terminal pyrimidine nucleotide and 
the sub-optimal in crystallo reaction conditions.  Steady state kinetic 
measurements have not yet been accurately collected in solution for S113A 
mutant Pol η extending a dT terminated primer, but initial experiments indicate 
the activity in solution is significantly lower than WT.  The reduced catalytic rate 
of S113A Pol η on dA terminated primers, despite proper dATP binding and 







Figure 12. Active site conformation and reactivity of a dA terminated primer 
within S113A Pol  
Left: 2Fo-Fc (1σ) superimposed on the 0 sec S113A Pol  - dA terminated primer 
structure.  Right: 2Fo-Fc (1σ) and Fo-Fc (3σ) maps calculated omitting the 
product conformation (shown in blue) superimposed on the 230s S113A Pol  - 
dA terminated primer structure.  Density for the new bond is present between the 





4.5. The ground state to reactant state transition is slower in S113A 
mutants than in wild type Polymerase η 
 Loss of activity for the S113A mutant in solution cannot be fully explained 
by unstable binding of the primer, since dA terminated primers, which are stable 
in the S113A Pol η active site, still result in activity loss in solution.  In good 
agreement with the solution kinetics, the S113A mutant reacted slower in 
crystallo than WT.  Three major changes occur prior to bond formation that can 
account for reduced rate: Mg2+ binding, GS to RS transition, and primer 
deprotonation.  Omit maps for the O3´ and C3´ atoms of the terminal base, 
calculated for the early time points of a WT and S113A Pol η extending a dA 
terminated primer, showed a marked delay in movement of the 3´-OH from the 
GS position to the reaction competent RS position (Fig. 13A and B).  WT Pol η 
has a significant RS population at the 40 sec time point, while the S113A mutant 
has no RS population until 140sec.  Additionally, the GS to RS transition is never 
fully complete in the S113A mutant, showing a significant GS population 
persisting beyond 5 minutes.  The delayed GS to RS transition in the S113A 
mutant results in reduced overall catalytic rate, as measured in solution.  The 
transition step from a GS to RS complex was only recently observed in Pol η 
structures 27.  In the previously reported WT Pol η in crystallo reaction, the RS 
was formed rapidly and a delay was observed between the RS appearance and 
the beginning of product formation.  Thus, for WT Pol η the GS to RS transition is 
not considered to be the rate-limiting step27.  However, for the S113A mutant, the 
GS to RS transition appears to be the slowest step in our in crystallo reaction, 
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suggesting that one role S113 serves is to accelerate the transition of primer end 
to the reaction-ready state.  This role is likely accomplished by the switch of the 
S113 hydrogen bond interaction from the 3´-OH to E116 upon binding of Mg2+ to 
the A-site seen in WT time courses 27. 
 
 
Figure 13. The ground state to reactant state transition rate is reduced by 
S113A mutation 
  A. Fo(WT 0sec-300sec)-Fc(WT 0sec) omit maps (3.5σ) of the C3´ and O3´ atoms 
superimposed onto the 0 sec WT Pol  - dA terminated primer complex.  GS and 
RS positions are indicated with arrows.  Product density is circled in red. 
   B. Fo(S113A 0sec-300sec)-Fc(WT 0sec) omit maps (3.5σ) of the C3´ and O3´ atoms 
superimposed onto the 0 sec WT Pol  - dA terminated primer complex. GS and 




4.6. RNA terminated primers rescue S113A Polymerase η activity to wild 
type levels by eliminating the requirement for a ground state to reactant 
state transition 
 To investigate the effect of the GS to RS transition rate on the overall 
activity, primers terminated with RNA bases were used to measure steady state 
extension rates in solution.  Deoxyribonucleotides in a double helix have a strong 
bias for C2´-endo pucker of the ribose group, while ribonucleotides in a double 
helix exist exclusively in the C3´-endo pucker conformation 107.  Extension of 
RNA terminated primers is catalyzed by WT Pol η at a rate comparable to DNA 
primers.  For S113A mutant Pol η, RNA terminated primers restore its activity to 
near WT levels (Fig. 14A).  Both normal RNA bases and modified RNA bases 
containing fluorine at the 2´ position were able to rescue the defect, indicating 
that the identity of the 2´ group was not important for the rescue.  The static 
structure of S113A Pol η bound to an rA terminated primer with Mg2+ and 
dAMPNPP was solved.  Consistent with the known sugar pucker bias, the 
terminal primer RNA base adopts a C3´-endo pucker and the base undergoes a 
slight propeller twist but the active site remains otherwise unaffected (Fig. 14B).  
This indicates that the altered sugar pucker is responsible for the rescue of 
S113A activity by removing a slow kinetic step prior to formation of the RS, seen 
at equilibrium in the static structure.   
 Time resolved in crystallo structures were collected of S113A mutant Pol η 
extending an rA terminated primer, to visualize the effect of the sugar pucker 
change on the GS to RS transition. Unlike the dA terminated primer, prior to Mg2+ 
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addition, the 3´-OH of the rA terminated primer is positioned in the RS 
conformation, despite no Mg2+ being bound in the A-site (Fig. 14C).  Throughout 
the reaction, no GS population was detected (Fig. 14D).  Due to the sugar pucker 
bias of the RNA ribose ring, the 3´-OH is occluded from the GS conformation, 
forcing it to adopt the RS position.   Thus, the GS to RS transition is no longer 
required, alleviating the kinetically slow GS-to-RS transition in the mutant and 
resulting in restored activity.  The RS and C3´-endo positioned primer did appear 
to reduce the incoming nucleotide affinity, resulting in reduced occupancy for the 
dATP, but did not affect the reaction in fully bound complexes. The S113A 
activity on RNA primers is only rescued back to the WT level, suggesting the GS 






Figure 14. The intrinsic C3'-endo sugar pucker bias of RNA terminated 
primers rescues S113A Pol η activity 
A. Steady state kinetic profiles of WT and S113A mutant Pol η extending primers 
terminating in dA/rA/2´fluoro-dA.  Kinetic parameters for each profile are listed in 
table 2.  B.  Structural alignment of S113A Pol η active sites bound to dA or rA 
terminated primers.  The dA primer structure is shown in semi-transparent blue 
sticks and the rA primer structure is shown in colored sticks (yellow incoming 
dAMPNPP, salmon protein residues, and grey primer).  The pucker change of 
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the terminal primer base is labeled.  C. 0 sec structure of S113A Pol η bound to 
an rA terminated primer and masked with 2Fo-Fc map (1σ). The rA primer is 
bound in the RS position prior to A-site Mg2+ addition/binding.  D. Fo(S113A + rA 
primer 0sec-300sec)-Fc(WT + dA primer 0sec) omit maps (3.5σ) of the C3´ and 
O3´ atoms superimposed onto the 0 sec WT Pol η - dA terminated primer 
complex.  GS and RS positions are indicated with arrows.  Product density is 
circled in red. 
 
4.7. Deprotonation is not dependent on the transiently 3´-OH associated 
water observed in time-resolved Pol η structures 
 The time resolved structures of WT Pol η extension reported by Nakamura 
et al showed that two Mg2+ ions are essential to align the primer 3´-OH with 
regard to the α-phosphate of the incoming dNTP in the RS 27.  Formation of the 
RS took place within 40 sec after Mg2+ addition.  However, there is a significant 
time delay after both Mg2+ ions are bound (RS), during which the reactants seem 
to be perfectly aligned but before the nucleophilic attack and new phosphodiester 
bond take place, beginning at 80sec.  The delay suggests that a slow chemical 
change, which may involve subtle conformational changes, is required to reach 
the transition state and complete catalysis.  This slow step appears to be the 
rate-limiting step of WT Pol  catalysis.  Deprotonation of the 3´-OH is a 
prerequisite for the nucleophilic attack, and could be the rate-limiting step that 
corresponds to the delay between binding of Mg2+ ions and phosphodiester bond 
formation45. The RS delay ends when density appears for a water molecule that 
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hydrogen bonds directly to the 3´-OH group, termed the transient water because 
it disappears due to a steric clash after new phosphodiester bond formation27 
(Fig. 15A).  The transient water appearance correlates temporally with 
phosphodiester bond formation, suggesting that it may be the general base that 
extracts the proton from the 3´-OH or serve to accept the 3´-OH proton once 
otherwise prompted to disassociate.  Steitz has previously proposed that the two 
Mg2+ ions play the key role of the general base28.  Since the 3´-OH is directly 
coordinating the A-site Mg2+ ion in the active site, its pKa can be dramatically 
reduced, promoting deprotonation.  However, Mg2+ can only prompt the 
disassociation of the proton; it cannot accept the displaced proton.  The transient 
water is positioned well to play the role of proton acceptor (Fig. 15A). 
 To investigate the role of the transient water in deprotonation of the primer, 
the structure of WT Pol η bound to a rA terminated primer and dNMPNPP was 
solved.  The 2´-OH moiety occupies a position in the RS conformation that 
occludes the transient water site (Fig. 15A).  Despite the absence of the transient 
water, the reaction proceeds in solution at a nearly unchanged rate, indicating 
the deprotonation mechanism was not significantly disrupted by the loss of the 
transient water.  However, the 2´-OH, occupying the transient water site, is also 
competent to participate in proton shuttle chemistry.  Using a water-mediated 
proton transfer mechanism, in which protons rearrange their bonding within a 
hydrogen bond network, the 2´-OH could accept the 3´-OH proton while 
transferring its proton to solvent.   Consistent with such a transfer, a water is 
seen in structures with RNA terminated primers that hydrogen bonds to the 2´-
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OH (Fig. 15A).  The modified RNA base 2´-fluoro-dA was tested as a more 
effective block of proton transfer through the transient water site, because the 
fluorine atom is not a proton acceptor.  In solution Pol η extends 2´-fluoro-dA 
terminated primers efficiently, demonstrating the transient water, though 
temporally correlated to bond formation, is not necessary for catalysis or primer 
deprotonation /shuttling (Fig. 15B).   
   
 
Figure 15. Primer deprotonation during Pol η catalysis does not require the 
transient water 
A. Structural alignment of the static Reactant State structures of WT Pol η bound 
to dA (semi-transparent blue sticks) and rA (grey and yellow sticks) terminated 
primers.  The transient water location is shown as a semi-transparent sphere.  
The secondary water of the rA structure is shown as a red sphere.  Hydrogen 
bonds between the terminal primer sugar groups and the waters are shown with 
dashes.  B. Steady state kinetic profiles of WT Pol  extending primers 
terminated in dA/rA/2´fluoro-dA.  
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4.8. The proton departure path may be variable 
 I have shown that neither the S113 residue nor the transient water is 
necessary to accept the primer proton during deprotonation (Fig. 10A and 13B).  
To identify other possible proton carriers the static structure of WT Pol η bound to 
the 2´-fluoro-dA terminated primer with Mg2+ and dAMPNPP was solved to 1.31Å.  
The high resolution ensures that even weakly bound groups and solvent will be 
observable.  Candidate proton carriers were identified using the criteria that they 
must be as least proximal enough to the 3´-OH to engage in a hydrogen bond, 
3.2Å or less.  Four groups were 3.2Å or closer to the primer 3´-OH: D115 (Oδ), 
E116 (Oε), dAMPNPP (αO), and a water that directly coordinates the A-site Mg2+ 
(Fig. 16).  The non-bridging oxygen of the α-phosphate is coordinating the A-site 
Mg2+ ion and has an extremely low intrinsic pKa value, making it a very unlikely 
proton acceptor 108.  The acidic residues D115 and E116 are also directly 
coordinating the A-site Mg2+ and thus have lowered pKa values due to 
coordination of the Mg2+ ion53, similar to the primer.  The residue homologous to 
E116 in DNA Pol β has been implicated as the proton acceptor during 
polymerase catalysis, and consistent with this conclusion its mutation reduces 
activity dramatically 33, 48.  However, due to E116’s role in coordination of the 
catalytic Mg2+, mutational approaches are unable to unambiguously demonstrate 
that activity loss is due to a deprotonation defect rather than disruption of proper 
Mg2+ coordination.  The final candidate, the water proximal to the 3´-OH, is the 
only solvent ligand of the A-site Mg2+ ion.  This A-site Mg2+ water has been 
previously proposed to directly accept the 3´-OH proton in the mechanism of 
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Dpo4 and Pol β using QM/MM simulations 45, 50.  Though this water is directly 
coordinating Mg2+ as well, it is capable of rearranging its O-H bonds with other 
waters with which it hydrogen bonds, allowing for continued coordination of the 
catalytic Mg2+ while shuttling the proton out to bulk solvent via a water mediated 
proton transfer mechanism.  Blocking of this site is not experimentally tractable, 
so this proton path also cannot be unambiguously verified. 
 Efforts to identify the proton acceptor in polymerase catalysis have not 
converged onto a consensus location.  I propose that this is due to the nature of 
the polymerase two metal ion catalysis mechanism.  The orientation of the primer 
proximal to the Mg2+ cluster favors the deprotonated 3´O state, providing the 
energy required to deprotonate the primer35, 53, 109.  The proton acceptor is thus 
not required to be a strong general base, such as those used in other acid/base 
catalysis mechanisms.  Instead, the polymerase deprotonation pathway may not 
use one fixed proton acceptor but instead be capable of using multiple groups, 
either residues or solvent, as has been proposed in QM/MM simulations of Pol β 
45.  Unfortunately, redundant routes for the proton out of the active site impede 
identification by traditional mutagenesis.  A variable proton acceptor and path 
would account for the inability to identify a singular general base for polymerase 




Figure 16. Identification of alternate deprotonation routes for the 3´OH 
proton 
A. The structure of WT Pol η bound to 2´-fluoro-dA terminated primer is shown 
with the primer in grey, dAMPNPP in yellow, and protein residues in salmon.  
Yellow dashes connect the 3´-OH to all proximal proton acceptors (<3.2Å).  The 
red dash indicates the hydrogen bond network available at the A-site 
coordinating water for water mediated proton transport.  B. Diagram of possible 





5. Phenanthriplatin, a novel chemotherapeutic candidate, 
induces cytotoxicity through potent inhibition of both 




5.1. Phenanthriplatin-dG lesions stall replicative and TLS DNA 
polymerases at the extension step of lesion bypass 
 To investigate the effects of phenanthriplatin on DNA synthesis, I first 
determined the phenanthriplatin bypass efficiency of a replicative DNA 
polymerase (Klenow fragment) and a variety of human TLS polymerases. The 
TLS polymerases studied included the A-family Pol , B-family Pol ζ, and Y-
family Pol  and Pol η (Fig. 17).  Collaborators in the Lippard lab at MIT 
generously supplied template DNA where only a single dG that was adducted 
with phenanthriplatin to form a single adduct for bypass. Each polymerase was 
able to catalyze the insertion step and incorporate a nucleotide opposite the 
phenanthriplatin-dG adduct with an apparent rate comparable to that obtained 
using undamaged DNA. Pol , ζ, , and the Klenow fragment all failed, however, 
to incorporate a nucleotide after the phenanthriplatin lesion and largely stalled at 
the +1 extension step. Only Pol η was able to catalyze the +1 extension with 




Figure 17. Comparison of run-off primer extension assays of Pol η, κ, , or 
the Klenow fragment using undamaged or phenanthriplatin damaged DNA 
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The DNA substrates are shown, the damage site is colored red, and the “/” 
indicates a nick.  Polymerase concentrations used in the gradients were 0, 2, 10, 
and 50 nM.  For Pol ζ the concentrations used were 0 and 50nM. 
 
 
5.2. Fidelity of incorporation opposite phenanthriplatin-dG 
 In addition to the efficiency of TLS, the fidelity of bypass is also important 
to maintain genomic stability. TLS polymerases are often specialized to bypass 
their corresponding lesions with the highest fidelity possible80.  For example, 
during bypass of two crosslinked thymine bases (CPD) on the template strand, 
Pol η preferentially incorporates two dATPs opposite the adduct.  Some 
mutations do still occur, however Pol  reduces the mutation rate due to CPD 
damage 110.  For phenanthriplatin, all polymerases tested are capable of inserting 
opposite the damaged dG. The fidelity of insertion was measured for each of the 
polymerases using a nucleotide preference assay (Fig. 18A).  The fidelity of 
insertion was very high for all polymerases tested.  In fact, Pol η appears to have 
the lowest fidelity at the insertion step, likely due to the openness of the Pol η 
active site.  This result suggests that the adducted dG is still able to bind in a 
nearly normal position within the active sites of these polymerases and form a 
Watson-Crick base pair with the incoming nucleotide.  Given the size of the 
phenanthriplatin adduct, correct positioning of the damaged dG in the templating 
base position may requires considerable rearrangement of the phenanthridine 
ring moiety (Fig. 4B).  Consistent with this theory, nucleotide incorporation by 
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high fidelity replicative polymerases opposite the bifunctional and sterically 
constrained cisplatin adduct is stalled 25. 




Figure 18. Fidelity of TLS bypass of a phenanthriplatin-dG adduct 
A. Fidelity of Pol η, Pol ζ, Pol , Pol , and the Klenow fragment bypassing of 
phenanthriplatin-dG at the nucleotide insertion step.  B. Fidelity of Pol η bypass 




5.3. Polymerase η bypasses phenanthriplatin-dG at low efficiency 
 The catalytic efficiency and fidelity of Pol η during the first three 
incorporation steps of TLS were determined by using a DNA oligonucleotide with 
a phenanthriplatin-dG adduct and normal DNA of identical sequence (sequences 
shown in Table 3).  Under steady state conditions primers were extended one 
nucleotide by Pol , and the extended primers were visualized by gel 
electrophoresis and fit to the Michaelis-Menten equation to determine steady 
state kinetic parameters. Pol η accurately incorporated dC opposite the 
phenanthriplatin-dG with a respectable catalytic efficiency (kcat/KM), which is 35% 
of that obtained with undamaged DNA (Fig. 18B, Table 3). The catalytic 
efficiency dropped to 5% and 4% at the +1 and +2 extension steps, respectively, 
for DNA platinated with phenanthriplatin. The large reduction in efficiency of the 
+1 extension step using platinated DNA is due to a ~6-fold increase in the KM, 
indicating disruption of dNTP binding. The +2 extension step with platinated DNA 
displayed a 6-fold reduction of kcat and a 4-fold increase of KM, as compared to 
those values obtained when observing normal DNA extension. As a result, this 
step has a relative efficiency similar to that of the +1 extension step. Despite the 
overall reduced efficiency of Pol η in primer extension after the phenanthriplatin-
dG lesion, its fidelity during both extension steps remained high (Fig. 18B). The 
absence of stalled intermediates beyond the +2 extension step in the run-off 
assays using platinated DNA (Fig. 17) suggests that the inhibitory effects of 
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phenanthriplatin begin to diminish after the +2 extension step because the lesion 
is translocated farther upstream from the active site. 
 The kinetic profile of phenanthriplatin TLS by Pol η is reminiscent of 
cisplatin TLS 32, in that Pol η becomes rapidly less efficient in the extension steps 
(Table 3). At each step, the efficiency of phenanthriplatin bypass by Pol η is 
about half that of cisplatin bypass. In contrast to the efficient extension beyond 
cisplatin adducts by Pol ζ, here Pol ζ was stalled by phenanthriplatin after 
insertion of a single nucleotide and failed to efficiently extend the primer (Fig. 17). 
It has been proposed for cisplatin bypass that Pol η is replaced by Pol ζ during 
the extension steps, which improves the efficiency of these steps 32, 84, 111. 
Improved efficiency of the extension steps, due to exchange of Pol η for Pol ζ, 
leaves the second insertion effectively the lowest efficiency step of cisplatin 
bypass, having 47% of the efficiency observed for incorporation using 
undamaged DNA 32. Pol η appears to be the only DNA polymerase capable of full 
TLS past the phenanthriplatin-dG adduct.  No higher efficiency polymerase can 
replace Pol η in the manner proposed to occur in the bypass of cisplatin. Thus, 
phenanthriplatin bypass has two consecutive low catalytic efficiency steps, each 
with 4-5% of the normal efficiency, which may combine to increase the toxicity of 





Table 3. Steady state kinetic measurements for each step of Pol  bypass 
of phenanthriplatin adducted DNA  
 









6. Structural features unique to Pol η enable TLS of 
phenanthriplatin-dG  
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6.1. Polymerase η structure in the insertion step is not affected by 
phenanthriplatin damage  
 The crystal structure of the ternary complex of Pol η (1-432aa), DNA with 
phenanthriplatin-dG at the templating position, and a non-hydrolysable 
dCMPNPP nucleotide was determined at 1.55 Å resolution. The insertion 
complex structure is virtually superimposable on that of an undamaged structure 
(pdb code 4DL3) with a root-mean-squared deviation (RMSD) of only 0.33 Å over 




The phenanthriplatin-dG is shown in magenta. Protein and DNA from the 





Figure 19. Superposition of the Pol η phenanthriplatin insertion structure 
upon the structure of Pol η bound to undamaged DNA (4DL3) 
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6.2. The CPD-binding pocket of Polymerase η accommodates the 
phenanthriplatin adduct during the insertion step 
 In the insertion complex, the phenanthriplatin modified dG base forms a 
canonical Watson-Crick base pair with the incoming dCMPNPP (Fig. 20A). Two 
conformations of the phenanthriplatin-dG lesion are discernible. The electron 
density for the Pt atom is observed for both conformations, but the aromatic rings 
of phenanthriplatin are only observed for the major conformation with weak 
density (Fig. 20B). The major conformation of the phenanthridine ligand 
corresponds to the same conformational isomer that was observed to form 
preferentially in small molecule models of the phenanthriplatin-DNA lesion 91. The 
two conformations of the templating base are related by a ~15° propeller rotation 
about the base-pair plane, with ~70% occupancy for the major and ~30% for the 
minor species. Phenanthriplatin forms a covalent bond to the N7 of dG in the 
major groove. The phenanthridine ligand is oriented toward the 5´ end of the 
template strand and interacts with the finger domain of Pol η.  Pol η has a pocket 
surrounding the templating base that accommodates UV-induced cyclobutane 
pyrimidine dimers (CPD’s) or the downstream base of an undamaged DNA 
template strand 25. This pocket is used in the cisplatin bypass mechanism to 
accommodate the 5´-dG of the cisplatin cross-linked guanine nucleotides 32. The 
present structure reveals that, during phenanthriplatin TLS, the pocket can 
accommodate the phenanthriplatin adduct during formation of the insertion 





Figure 20. Pol η accommodation of phenanthriplatin adduct in the insertion 
step complex 
A. The templating base pair. The incoming nucleotide is shown in yellow, the 
phenanthriplatin damaged dG is shown in orange, and the phenanthriplatin is 
shown in magenta. Watson-Crick base pairing interactions are illustrated with 
dashed lines.  B. Phenanthriplatin binding pocket. The phenanthridine ligand fits 
into the CPD-binding pocket in the finger domain shown in green. The blue 2Fo-








6.3. Flexibility and conformational bias of phenanthriplatin-dG 
 Monofunctional platinum adducts that form a covalent bond to a single 
nucleotide, such as the one formed by phenanthriplatin, are substantially more 
flexible than CPDs or cisplatin adducts, which crosslink two adjacent bases. 
Moreover, rotation about Pt–NP and Pt–NG is facile 
91. This high flexibility 
explains the weak electron density observed for the phenanthridine moiety, 
because the binding pocket in Pol η is large enough to permit ~10° of rotation 
about Pt–NG and ~20° of rotation about Pt–NP (Fig. 21). The flexibility of 
phenanthriplatin may also allow it to reposition so as to be accommodated by 
other polymerases during the insertion step. This hypothesis would explain the 
activity observed for Pol , ζ, , and the Klenow fragment in the insertion step, 




The rotational extremes possible for the phenanthridine ligand are shown in 
magenta.  The polyhydrocarbon rings are able to rotate ~10° about the Pt–NG 




Figure 21. Model of the flexible range of phenanthriplatin within the CPD-
binding pocket of Pol η 
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6.4. Polymerase η-phenanthriplatin damaged DNA complex in the 
extension step reveals large conformational changes in the downstream 
DNA 
 The crystal structure of the ternary complex of Pol η (1-432aa), DNA 
platinated at a dG base-paired with the 3´ end of the primer strand, and a non-
hydrolysable dGMPNPP base-paired with the dC downstream (+1) of the lesion, 
was determined at 2.8 Å resolution. Consistent with studies of Pol η TLS of other 
bulky DNA lesions, the protein structure in the phenanthriplatin +1 extension step 
remains relatively unchanged by the adduct, resulting in a pairwise Cα RMSD of 
0.28 Å from an undamaged structure25, 32. A 2.9° rotation of the Little Finger 
domain away from the catalytic core is observed together with an adjustment of 
the template strand (Fig. 23A). The DNA, however, undergoes large 
conformational changes near the lesion to accommodate phenanthriplatin during 






Figure 22. Structure of Pol η - phenanthriplatin-dG DNA complex at the +1 
extension step 
Undamaged DNA from a normal Pol η ternary complex structure (4DL3) is 
superimposed onto the +1 extension complex and shown in semi-transparent 
blue to demonstrate the DNA conformational changes.  Displacement of the 
downstream DNA backbone and distortion of the templating dC are indicated 
with arrows. Two conformations of phenanthriplatin, the templating base, and the 
incoming nucleotide are present. The major conformation has 80% occupancy 
and is shown in magenta. The minor conformation has 20% occupancy and is 
shown in cyan. 
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The phenanthriplatin-dG and downstream DNA of the template strand are 
no longer in the canonical B-form, but the upstream duplex DNA retains B-form 
character because of extensive interactions with the little finger domain of Pol η. 
This phenomenon is known as the molecular splint effect.  As evident in CPD 
TLS structures, a critical β-sheet involving amino acids 316-324 runs parallel to 
the template strand and forms hydrogen bonds between the three phosphate 
groups immediately upstream of the platinum adduct and every other main-chain 
amide (Fig. 23B) 25. In the +1 extension complex, Arg, Lys, and Thr side chains 
also hydrogen bond with the phosphosugar backbone of the template strand and 
reinforces B-form structure. The distortion induced by the phenanthriplatin lesion 
is mainly absorbed by rotation of the ribose rings of the upstream bases and a 





Figure 23. The molecular splint of Pol η stabilizes the damaged upstream 
template DNA in B-form helical structure 
A. The +1 extension complex structure superimposed with the normal Pol η 
complex (pdb code 4DL3).  The extension complex is colored by domain and the 
undamaged structure is semitransparent blue.  The shift in DNA position 
downstream of the adduct is shown with a straight arrow and the rotation of the 
Little Finger domain is denoted with curved arrow.  The finger domain is omitted 
for clarity.  B. The interactions of the molecular splint.  The beta sheet in the little 
finger domain that is responsible for stabilizing the template strand is shown in 
stick representation.  The splinting interactions between the little finger domain 
and template strand are shown as black dashes. 
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6.5. The templating base is displaced by phenanthriplatin in the 
extension complex 
In the +1 extension complex, the phenanthridine moiety extends toward 
the 5´ end of the template strand (Fig. 22). The adduct is present in two 
conformations that are related by 180° rotation about Pt–NP and 24° rotation 
about Pt–NG. The flexibility about the Pt–NP bond is the same type observed in a 
disordered small molecule structure solved by our collaborators, the Lippard lab 
at MIT91. The two lesion conformations in the macromolecular structure are 
discernible, but occupy overlapping space (Fig. 24A). As in the case of the 
insertion complex, the orientation of the phenanthridine ligand in the major 
conformation corresponds to the structure that was observed during previous 
studies with small molecule models of the phenanthriplatin-dG complex 91. The 
two conformations of the phenanthridine ligand distort the templating dC 
differently, resulting in two conformations for this nucleotide. In the major lesion 
conformation (80%) the phenanthridine moiety would clash with the templating 
base dC if it were in its normal position and, consequently, the templating base is 
shifted by a ~75° propeller twist. In this twisted orientation, the templating base 
forms - stacking interactions with the phenanthridine rings. The dA(+2) residue 
located on the template strand downstream of the lesion forms a base stacking 
interaction with the phenanthridine ligand opposite the templating dC. Distortion 
of the templating base prevents it from forming a Watson-Crick base pair with the 
incoming nucleotide and may thus explain the large increase in KM of the +1 
extension step in the presence of the adduct. In the minor conformation (20%), 
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the orientation of the phenanthridine moiety permits the templating dC to assume 
a near-normal position, with only a slight twist to form a planar Watson-Crick 





Figure 24. Double conformations of the phenanthriplatin adduct and 
templating base in the +1 extension complex 
A. Two conformations of phenanthriplatin in the +1 extension complex and cis-
[Pt(NH3)2(Gua-Et)(Am)](OTf)2, where Gua-Et is a 9-ethylguanine, Am is 
phenanthridine, and OTf is trifluoromethanesulfonate. In the macromolecular 
structure (left), the major conformation is in magenta and minor conformation in 
cyan.  The Fo-Fc omit map was calculated by removing the phenanthriplatin 
adduct and contoured at 3.0 σ. Two states of the disordered small molecule 
structure are shown in ball-and-stick mode (right).  The small molecule structure 
was solved by collaborator Timothy Johnstone of the Steve Lippard lab at MIT.  B. 
Template base minor conformation omit map.  The Fo-Fc (green) and 2Fo-Fc 
(blue) maps contoured at 3.0 σ and 1.0 σ, respectively. The omit map was 
calculated omitting the minor conformation, and the 2Fo-Fc map masks the 
structure of the major conformation (magenta). The minor conformation of the 




6.6. Misalignment in the active site results in low efficiency of primer 
extension during the first extension step after phenanthriplatin-dG 
Of the two alternate conformations, the minor species of the incoming 
dGMPNPP is shifted 0.5 Å into the minor groove (Fig. 25A). This shift is caused 
by hydrogen bond interaction with the shifted templating dC conformation (Fig. 
25A).  The major dGMPNPP conformation makes no hydrogen bonds with the 
templating dC, and is thus less shifted. The fidelity of Pol η in the +1 extension 
step suggests that the base pair interaction must be preserved, and therefore the 
minor conformation is probably the catalytically competent one (Fig. 18B). 
In the major conformation, the platinated dG base is displaced ~1.3 Å into 
the major groove to avoid steric clash with the templating base. The primer 
strand terminal dC remains hydrogen bonded to the phenanthriplatin-dG, and 
through base pairing it pulls the primer 3´-OH to a distance 1.2 Å farther away 
from the active site than occurs in undamaged structures (Fig. 25B). The 3´-OH 
is no longer within coordination distance of the active site Mg2+, nor is it close 
enough to the α-phosphate of the incoming nucleotide to participate in the 
phosphodiester bond formation (Fig. 25C) 27, 112. Conversion from this 
catalytically incompetent (major) conformation to the competent (minor) 
conformation would require separation of the base pair between phenanthriplatin-
dG and the primer. The energy required to break the base pair is probably a 





Figure 25. Misalignment of the active site in the +1 extension complex 
A. Templating base pair of the +1 extension complex. In the minor conformation 
(cyan), hydrogen bonds are seen between the templating dC and incoming 
nucleotide (black dashes). The undamaged templating base pair is shown in 
semi-transparent blue for displacement reference. The phenanthriplatin adduct in 
the -1 position is also shown.  B. Phenanthriplatin-dG:primer 3´ base pair of the 
+1 extension complex. The undamaged base pair is shown in semi-transparent 
blue for displacement reference. The 3´ base of the primer is shown in light 
orange and the adducted dG is shown in dark orange. The black dashes show 
the base pairing interaction and the arrow indicates the movement of the 3´-OH 
away from the active site.  C. Primer misalignment in the extension step. 
Undamaged DNA-Pol η complex (3MR2) is shown in semi-transparent blue. The 
two conformations of the incoming nucleotide are shown in magenta and cyan 
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(major and minor conformations, respectively) and primer terminus in light 
orange. Yellow dashes indicate the coordination of the active site magnesium 
ions. The primer 3´-OH is displaced 0.7 Å from the undamaged position and the 
increased distances to the catalytic Mg2+ and α-phosphate of the incoming 
nucleotide are shown in black dashes. 
 
 
6.7. DNA backbone displacement during phenanthriplatin TLS is 
accommodated by the CPD-binding pocket in the Pol η finger domain 
 In the +1 extension complex, the phenanthriplatin ligand occupies the site 
that is normally occupied by the phosphate backbone of the templating 
nucleotide in undamaged DNA-Pol η complexes (Fig. 26A). As a result, the 
phosphate backbone is moved 4.6 Å toward the fingers domain. This new 
backbone path is accommodated by the CPD-binding pocket above the template 






Figure 26. The CPD-binding pocket of the Pol η finger domain 
accommodates a large DNA backbone rearrangement in the +1 extension 
complex  
A. Superposition of +1 extension complex with phenanthriplatin-damaged 
(orange) and undamaged DNA (light blue) bound to Pol η (4DL3). Cartoon traces 
the path of the DNA backbone and phenanthriplatin-dG is shown as sticks.  
Phenanthriplatin major and minor conformations are shown and both clash with 
the normal DNA backbone. The Pol η finger domain pocket is colored in green.  
B. Superposition of the phenanthriplatin-dG DNA from the +1 extension complex 
(orange) and the insertion complex DNA (red) bound to Pol η.  Cartoon traces 
the path of the DNA backbone and phenanthriplatin-dG is shown as sticks. The 
Pol η finger domain pocket is colored in green. The pocket accommodates the 
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phenanthriplatin damage present in the insertion complex and the displaced DNA 
backbone of the +1 extension complex. 
 
 
 For example, the altered DNA backbone observed for Pol η, when 
modeled into the Pol κ structure, clashes with loop residues (aa. 133-135) of the 
Pol κ fingers domain (Fig. 27). In the +1 extension step, the expanded active site 
and finger domain pocket of Pol η are required in order to accommodate the 
platinum adduct, which may explain the strong stalling observed with all DNA 




The Pol κ DNA is shown in teal and phenanthriplatin-damaged DNA from the Pol 
η extension complex is shown in orange. S134 (yellow) clashes with the 
backbone of the damaged DNA. M135 (yellow) clashes with the phenanthridine 
ligand and with the major conformation of the templating dC (orange sticks). 
 




Figure 27. Model of the phenanthriplatin extension complex of Pol κ 
demonstrates steric clashes responsible for stalling 
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7. Summary and Conclusions 
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7.1. Active site alignment and structural transitions required for efficient 
polymerization of DNA 
 The first structure of Pol η was of the yeast Pol η polymerase, solved by 
the Aggrawal group68.  This initial structure lacked DNA, metal ions, or incoming 
nucleotide but confirmed that despite low sequence conservation with 
polymerases of the A- and B-families, Pol η shared a similar fold7, 68.  Six years 
later, a ternary yeast Pol η structure with DNA, metal (Ca2+ instead of Mg2+), and 
incoming nucleotide was solved by the Carell group113.  This structure, however, 
did not represent a catalytically active form, as evidenced by a modeled primer 
3´-OH to α-phosphate distance of over 8Å.  The first catalytically competent 
structure of Pol η was solved using human Pol η by the Yang group25.  In the 
human Pol η structure, the active site resembled the architecture seen for 
polymerases of the A- and B-family polymerases104, 114 with two Mg2+ ions 
coordinated by three conserved acidic residues (Asp13, Asp115, and Glu116).  
The 3´-OH in this structure is also coordinating a Mg2+ ion (A-site) and is only 
3.3Å from the α-phosphate, consistent with distances observed in catalytically 
competent Pol β structures 29.  Time-resolved crystallographic structures of Pol η 
later demonstrated the primer 3´-OH only aligned for catalysis upon binding of 
the A-site Mg2+27.  Prior to Mg2+ binding, the 3´-OH was interacting with the S113 
residue in a ground state (GS), but upon Mg2+ binding the 3´-OH transitioned to 
coordinating the A-site Mg2+ in a reactant state (RS), aligned for catalysis27.    
Structure based alignment of Y-family polymerases, however, reveal that S113 
was a conserved position 102.  My research focus is on the alignment and 
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deprotonation of the 3´-OH in Pol η catalysis.  Due to S113’s proximity to the 3´-
OH and conservation, I hypothesized that S113 may play a role in primer 
deprotonation or alignment28.   
In this work I investigated the role of the conserved S113 position within 
the Pol η active site.  This site is also conserved across A- and B-family 
polymerases, and previous mutational studies of E. coli Pol I have identified 
reduced activity upon mutation, however, no function was identified54, 55.  
Mutation of Pol η S113 also reduces activity by ~4-fold, but my traditional static 
polymerase-substrate complex crystal structures of the mutant failed to identify a 
cause for reduced activity. Time resolved structural studies of the mutant reveal 
two defects in the S113A mutant: primer terminal base instability prior to Mg2+ 
binding and inefficient transition from the GS to the RS.  Conformational flexibility 
of the primer end in the active is much more pronounced than previous structural 
work suggested27.  Organization of the primer terminus prior to Mg2+ binding is 
dependent upon S113 in Pol η through direct hydrogen bond between the serine 
hydroxyl and the 3´-OH, stabilizing the primer in the GS.  Upon activation of the 
WT polymerase by binding of Mg2+ to the A-site, the primer transitions from the 
GS to RS, an essential pre-catalytic step that is not detectable using static crystal 
structures alone27.  Time resolved structures of S113A mutant visualized the 
inefficient GS to RS transition within the mutant active site, which is responsible 
the mutant’s reduced activity.  The GS to RS transition therefore is not automatic, 
but facilitated by the rearrangement of the S113 hydrogen bond network within 
the active site.  To investigate the effect of GS to RS transition, primers 
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terminated with RNA bases were used which are biased for the C3´endo sugar 
pucker conformation, due to a steric clash of the 2´-OH group with downstream 
nucleotides, in this case the incoming dATP.  Polymerization reactions using 
RNA terminated primers rescue the S113A mutant activity, and time resolved 
structures of S113A mutant extending RNA demonstrate the activity is rescued 
due to RNA’s intrinsic sugar pucker bias favoring the RS conformation.  This 
confirms the GS to RS transition defect is responsible for reducing S113A activity. 
Time resolved crystallography has enabled visualization of catalytic events 
and mutational effects previously not accessible with traditional crystallographic 
techniques.  Direct visualization removes the uncertainty in interpretation of 
kinetic phenomena and identifies the precise nature of kinetic events.  Though 
not applicable to all systems, further development and use of this technique can 
facilitate greater understanding of the subtle conformational changes critical to 
enzyme-catalyzed reactions. 
 
7.2. The polymerase active site promotes primer 3'-OH deprotonation, 
allowing the proton acceptor to be varied 
 Despite considerable effort in the polymerase field, a consensus on the 
identity of the general base that extracts the 3´-OH for polymerase catalysis has 
not been reached48-51.  This is primarily due to the intricate complexity of two 
metal ion catalysis, in which mutational effects of candidate residues on 
deprotonation versus coordinating the active site metal ions cannot be 
unambiguously parsed.  In lieu of mutational approaches, many QM/MM studies 
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have suggested a water molecule, and not a protein residue, as the most 
energetically favorable group to directly receive the proton50, 51.  The recently 
discovered water that transiently interacts with the 3´-OH immediately prior to 
catalysis in Pol η was a promising candidate to accept the 3´-OH proton25.  When 
I blocked the transient water site with a fluorine group, which is incapable of 
accepting a proton, Pol  remained active demonstrating that the transient water 
is not the sole, direct proton acceptor.  Only one other water is close enough to 
the 3´-OH to directly accept the proton, the water coordinating the A-site Mg2+.  
There is no straightforward means by which to block this water, so only in silico 
simulations will be able to shed light on a possible path for the proton to the 
metal water.  The alternative proton acceptors observed in the three different 
primer configurations with Pol η (normal primer, 2´-OH and 2´-F terminated 
primers) indicate that the route for the 3´-OH proton to depart is variable.  The 
impetus for deprotonation is being supplied by stable coordination of the 3´-OH to 
the Mg2+ ions35, 53, 109, lowering the energetic requirement for the strength of the 
general base to a level that multiple groups can facilitate deprotonation.   
 
7.3. Polymerase η as a target for anti-cancer chemotherapy 
 The platinum class of chemotherapeutics induces DNA damage in order to 
inhibit DNA replication76, 115.  Inhibition of replication allows for potent toxicity in 
rapidly dividing cancer cells, while mitigating effects on somatic tissues which 
rarely replicate. In somatic cells, which are no longer actively dividing, DNA 
adducts are removed by housekeeping DNA repair mechanisms74.  In actively 
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dividing cancer cell lines many of these DNA adduct will persist into S-phase, 
and TLS will be required to avoid replication fork collapse and apoptosis74.  
Inhibition of TLS polymerases would increase the toxicity of platinum agents in 
cancer cells that rely on TLS and give rise to greater efficacy of chemotherapy 
treatment.   
 I have identified an inhibitory small molecule binding site in the TLS 
polymerase .  I showed that dATP binds weakly at this site and is capable of 
inhibiting Pol .  I have not yet identified a high affinity inhibitor for this site, but 
using dATP as an initial template, I hope that rational design approaches will 
yield higher affinity inhibitors.  Such inhibitors, if used in conjunction with 
chemotherapy treatments such as cisplatin or oxaliplatin, whose efficacy is 
correlated to Pol η activity, could dramatically improve treatment outcomes. 
 
7.4. Inhibition of Polymerase η by monofunctional and bifunctional 
platinum chemotherapeutics 
The mechanism of action of current platinum-based chemotherapeutics is 
to damage DNA and inhibit cellular processes such as DNA replication to induce 
cell death76. My collaborators in the Lippard lab at MIT developed a new 
platinum-based chemotherapeutic candidate phenanthriplatin87.  Phenanthriplatin 
is a derivative of the most commonly used platinum chemotherapeutic, cisplatin, 
and I hypothesized that it may have a similar mechanism of action. I investigated 
first the efficiency with which polymerases from the A (Klenow fragment & Pol ν), 
B (Pol ζ), and Y (Pol κ & Pol η) families can synthesize DNA past 
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phenanthriplatin-DNA damage to determine if phenanthriplatin stalls replication 
polymerases.  Only the TLS polymerase Pol η is capable of fully bypassing the 
phenanthriplatin lesion. All other polymerases that I tested are able to insert a 
nucleotide opposite the phenanthriplatin-dG (the insertion step) but stall 
immediately after the lesion (the extension step), confirming that phenanthriplatin, 
like cisplatin, does inhibit high fidelity replicative polymerases32.  Replication past 
the lesion by Pol η is inefficient but appears to be error-free 82, 116.  Structural 
studies of Pol η at the insertion and +1 extension step reveal the uniquely 
enlarged active site of Pol η, which is evolved to TLS bypass UV lesions25, 
accommodates the phenanthriplatin lesion. Perturbation of the nascent base pair, 
primer alignment in the active site, and the downstream DNA conformation by 
phenanthriplatin adducts explains the inability to bypass phenanthriplatin as 
efficiently as bifunctional platinum adducts32, 87.  These results highlight that the 
cellular processing of phenanthriplatin is distinct from that of bifunctional platinum 
compounds such as cisplatin and oxaliplatin, in which one polymerase is typically 
employed for the insertion step and another for the extension steps32, 84, 94. 
Increased Pol η expression is a known resistance mechanism employed in 
cancer cells against treatment with the current bifunctional platinum compounds, 
reducing their curative potential82, 116.  Due to phenanthriplatin’s much more 
efficient inhibition of Pol , increased Pol η expression in cancer cells should 
confer significantly less survival advantage, suggesting phenanthriplatin may be 
useful against cancers that have already developed resistance, and may also 
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8. Appendix 1: Motility of kinesin motor proteins 
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8.1. Cellular functions of motor proteins 
 Eukaryotic cells are very large, highly structured systems.  In order to 
maintain cellular structure and provide efficient transport over the long distances 
within cells they have evolved active transporters117.  These intracellular 
transporters are the motor proteins kinesin, myosin, and dynein.  Motor proteins 
move along the filaments, made of either actin or microtubules (MT), that 
comprise the cytoskeleton.  Structural and single molecule studies of these motor 
proteins suggest that all three families use a mechanism similar to walking to 
produce movement along their cytoskeletal tracks118, 119.   
 A variety of cargos rely on active transport by motor proteins. Within the 
secretory pathway vesicles must be transported between the endoplasmic 
reticulum (ER), golgi cisterns, and plasma membrane.  Generally, vesicle 
movement between the ER and golgi is provided by dynein, while transport from 
the golgi to endosomes and the cell surface is provided by kinesins117.  Active 
transport, as opposed to diffusion, of vesicles in the secretory pathway is vital to 
ensure they reach the proper destination.  Active transport of daughter 
chromatids during mitosis is essential to ensure equal distribution of genomic 
content to the two daughter cells120.  Mitotic kinesins provide the force for 
separation of the chromatids during anaphase by sliding MTs of the mitotic 
spindles past one another120.  In this work, I focused on understanding the 




8.2. Kinesin structure and mechanism  
 All three motor protein families are thought to use a similar walking type 
mechanism to produce movement, often called a hand-over-hand mechanism118.  
Kinesin is the smallest and most well characterized of the three motor protein 
families, and has thus been the focus of efforts to describe the walking 
mechanism.  It is likely that activity and regulatory themes important to kinesin 
mechanism of motility will be applicable to all three motor families.   
 Though kinesin structure varies between subtypes, the general structure 
of kinesin family proteins consists of three domains: the motor domain, the stalk 
domain, and the tail domain (Fig. 28A).  In most kinesins the motor domain is 
located at the N-terminus of the protein121.  The motor domain is the defining 
feature of the kinesin family and is highly conserved between 14 kinesin 
subfamilies122.  It is a globular structure that houses both the ATPase active site 
as well as a MT binding site, and thus is also referred to as the MT binding head.  
The final few residues of the motor domain are known as the neck linker.  The 
neck linker is a flexible stretch of ~13 residues that connects the globular core of 
the motor domain to the stalk domain.  The stalk is dominantly α-helical domain, 
and the site of dimerization via the formation of a coiled-coil with another 
kinesin123. Electron microscopy has shown that the stalk domain of kinesin 
adopts an elongated conformation spanning up to 70nm in some cases124.  
Finally, the tail domain is located on the other end of the stalk and is responsible 
for binding of cargo.  Certain kinesin tail domains bind directly to their cargo 
molecules, while others require adapter proteins often called kinesin light chains.   
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 Kinesins produce movement along the microtubule in a defined direction, 
usually plus-end directed.  As a dimer, a kinesin alternates which head is bound 
to the MT in an asymmetric hand-over-hand fashion similar to human walking125, 
126.  Each step results in a net 8 nm movement, the distance between  and  
tubulin heterodimers, that is tightly coupled to the hydrolysis of a single ATP 
molecule127.  Whether a head is bound or unbound to the MT is determined by its 
nucleotide state, i.e. the identity of the nucleotide bound in its active site (ATP, 
ADP, or none). The head is bound when empty or with ATP and unbound with 
ADP128.  Thus, as a motor domain completes a full ATP hydrolysis cycle it will 
alternate between MT bound and unbound, completing a full step.  Key to its long 
distance transport is its ability to take many steps along a single microtubule 
track without detaching.  This ability is termed processivity.  Single molecule 
studies of kinesin motors have shown that kinesins have strong processivity, 
allowing them to travel several microns in a single run129, 130.  Processivity 
requires communication between the two motor domains to ensure that only the 
rear head detaches while the leading head remains bound to the MT to prevent 
complete disassociation.   
 The current model for communication between the MT binding heads 
relies on the neck linker and dimerization domain that connect them118, 131-133.  It 
is thought that tension is produced in the linker regions between the heads when 
both are bound to the MT.  The tension would then cause a conformational 
change in the rear head that leads to detachment from the MT134.  The rear head 
would then rebind ahead of its partner to complete a step.  Communication 
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between the heads in this model is thus dependent on the linker and stalk 
domains that connect them as well as the MT lattice structure.  Unfortunately, the 
current model does not fully explain some observed kinesin activities.  For 
example, in the absence of MT’s, kinesin has both a low and high affinity MT 
binding site that would not be predicted of a homodimer135.  Kinesin is also able 
to coordinate its binding to tubulin heterodimers in a fashion identical to binding 
to MTs, demonstrating that the heads are able to communicate in the absence of 
the MT lattice128.   
 An additional mechanism is needed to explain the communication 
between heads that occurs independent of tethering between the heads or the 
MT lattice.  Crystal structures of several kinesin MT binding heads have been 
previously solved.  In multiple structures of the mitotic kinesin Eg5 the heads 
appear to form a dimeric structure that likely would influence the enzymatic 
activity of their ATPase sites136, 137.  Such a direct interaction between heads 
could potentially explain the outlying data and represent a novel step in the 
kinesin walking mechanism.  The goals of this work were to detect and identify 
complexes formed between kinesin head domains and characterize their role in 






Figure 28. Kinesin structure and complex formation assays  
A. Domains of WT and truncated Eg5.  The general topology of the expressed 
protein is shown beneath.  B.  Gel filtration determined Eg5 constructs to be 
mono-disperse monomers in solution.  Shown is a chromatograph of Eg5 
monomers at ~8 mg/ml injection concentration and in the presence of ATP and 
ADP.  All nucleotide conditions tested resulted in similar profiles.  Multi-Angle 
Light Scattering (MALS) molecular weight measurement for the peak is shown in 
red and the predicted molecular weight of an Eg5 monomer is indicated in green.  
C. Crosslinking with BS3 cannot detect specific interaction between Eg5 
monomers.  Crosslinked bands are present at very high crosslinker 
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concentrations but form ladders, indicating these are non-specific crosslinks due 
to the highly concentrated reaction conditions.   
 
8.3. Direct communication between kinesin motor domains is not 
detected by crosslinking and size exclusion chromatography 
 To enable detection of direct interactions between MT binding heads, a 
truncated construct of the mitotic kinesin Eg5 that lacks the coiled-coil 
dimerization domain and cargo binding domain was created (Fig. 28A).  This 
construct retains only the MT binding head and has been shown to be 
monomeric in solution, which is essential for controlling its local concentration138.  
Importantly, the absence of the dimerization domain also eliminates any effects 
that tension may play in head communication.  The construct is bacterially 
expressed and purified to homogeneity. 
 In order to detect dimerization interactions between the monomeric head 
constructs, size exclusion chromatography was used.  Due to the nature of 
kinesin movement being linked to the ATPase cycles within the MT binding 
heads, any interaction would likely be dependent on the nucleotide state of the 
two heads involved.  Size exclusion runs were performed with monomeric Eg5 
heads with a variety of nucleotides (ATP, ADP, AMPNPP) as well as 
combinations of nucleotides to allow for detection of possible heterodimers.  In all 
conditions, a single mono-disperse peak was observed (Fig. 28B).  Multi-Angle 
Light Scattering (MALS) determine that these peaks corresponded to monomers 
in solution, indicating that no dimer formation was detectable.   
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 Any interaction between kinesin heads during kinesin walking would need 
to be weak or transient to allow productive walking.  Thus, I hypothesized that 
direct interaction between kinesin heads may be too transient or too weak to be 
detected by size exclusion chromatography.  For increased sensitivity a protein 
crosslinking assay was used.  Monomeric kinesin heads were crosslinked by 
BS3 in a variety of nucleotide conditions and in both the presence and absence 
of microtubules and depolymerized tubulin (Fig. 28C).  Similarly no significant 
crosslinking was observed between kinesin heads in any condition tested. 
 
8.4. Concentration dependent assays reveal no cooperativity between 
kinesin heads 
 Dimerization of kinesin heads to coordinate kinesin movements, no matter 
how transient or weak, would need to effect the ATPase activity of the heads in 
order to alter their MT binding state.  In order to detect dimeric Eg5 head 
complexes that have the ability to alter the ATPase activity I measured the 
catalytic activity (kcat) for ATP hydrolysis over a range of head domain 
concentrations.  At higher concentrations dimerization would be promoted and 
catalytic effects due to complex formation would be observable.  In initial 
experiments ATP hydrolysis appeared to increase sigmoidally with increasing 
head concentrations, consistent with a dimer complex forming at high 
concentrations that simulates the ATPase active site (Fig. 29A).  Because the 
nucleotide state of the head determines the MT binding affinity of the head, such 
a complex could contribute to coordination of the heads during movement along 
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a microtubule.  A similar phenomenon was observed for head domains of 4 other 
kinesins, KIF1A (monomeric family-3), DHC (dimeric family-1), KIF4B (dimeric 
family-4), and Ncd (dimeric family-14) (Fig. 29A).  Upon addition of microtubules, 
kinesin activity is stimulated over 60 fold, but kinesin concentration dependent 






Figure 29. Concentration independent ATPase activity of kinesin 
monomers 
A. Measurement of the steady state rate of ATP hydrolysis by kinesin monomers 
as a function of monomer concentration.  A hill coefficient of ~2 or greater was 
determined for all curves by fitting the data with a sigmoidal dose response 
model, which is represented by the solid lines.  B. Steady state ATP hydrolysis of 
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Ncd monomers in the presence and absence of polymerized microtubules (MT).  
Each curve is normalized independently due to the much higher overall rate in 
the presence of MTs.  C. Protein losses due to tube adsorption detected by 
measuring protein concentration after transferring a solution of kinesin monomers 
through 3 tubes.  All kinesin monomers had substantial losses due to adsorption 
despite ample (0.2 mg/ml) carrier BSA protein present in the buffer.  D. Steady 
state ATP hydrolysis of Eg5 monomers in the presence of 1 mM Triton X100, a 
detergent that eliminates tube adsorption.  Kinesin ATPase activity is 
independent of monomer concentration once tube adsorption is eliminated, 
indicating the concentration dependent activity observed previously was an 
artifact of the serial dilution protocol used. 
 
 Concentration dependent stimulation of kinesin activity appeared to 
demonstrate a regulatory kinesin head dimer could form, however in developing 
orthogonal assays (mutation based) this phenomenon was difficult to replicate 
and validate.  For example, the degree of stimulation was dramatically reduced if 
samples of kinesin heads were prepared with parallel dilution methods instead of 
serial dilution.  This lead me to be suspicious of dilution associated loss of protein 
concentration that could account for the apparent loss of activity at low 
concentrations, despite efforts to mitigate such losses with abundance BSA 
carrier protein in each reaction.  To determine if kinesin concentration was lost 
during serial dilution, a sample of kinesin monomers was transferred between 
tubes three times and the concentration measured to access loss due to tube 
 114 
binding (Fig. 29C).  After only three transfers, Eg5 kinesin head concentration 
dropped dramatically, indicating the concentration dependent stimulation 
phenomenon observed was only a dilution artifact.  This was confirmed by 
repeating the concentration dependence assay in the presence of 1 mM Triton X-
100, a detergent I found that reduces tube adsorption of kinesin heads.  In the 
presence of Triton, kinesin ATPase activity was independent of kinesin head 
concentration (Fig. 29D).  
  
8.5. Summary 
 I originally hypothesized that direct interaction between the two 
microtubule binding heads of a kinesin moving along a microtubule would 
coordinate movement of the heads.  Such coordination would require a direct 
interaction that affected the ATPase activity of the kinesin head, since the 
nucleotide state of a kinesin head is linked to it microtubule binding affinity.  
However, using size exclusion chromatography and protein crosslinking, no 
kinesin head dimerization interactions were detectable.  Additionally, kinesin 
microtubule binding heads do not affect the ATPase activity of other heads, even 
at very high concentrations that would promote dimerization or interactions if they 
existed. These results suggest that a direct interaction between kinesin head 
domains does not form or contribute to coordination of kinesin movements.  
However, it is important to note that due to the nature of my negative results a 




Cloning and expression and purification of kinesin microtubule binding 
domains 
 The microtubule binding head of a representative set of kinesin molecules, 
HsEg5 (aa1-368), MmKIF1A (aa1-355), HsKIF4B (aa1-349), DmKHC (aa1-342), 
and DmNcd (aa335-700), were cloned and inserted into the pET28 or pET21 
vector.  The HsEg5 construct had no tag while all others had a C-terminal 6xhis 
tag.  The HsEg5, MmKIF1A, and HsKIF4B constructs were expressed in BL21 
(DE3) Rosetta cells by growing to an OD~0.8 at 37°C and inducing with 0.5 mM 
IPTG for 4 hrs.  DmKHC and DmNcd constructs were expressed in BL21 (DE3) 
Rosetta cells by growing to an OD~0.8 at 37°C and inducing with 0.5 mM IPTG 
at 16°C for ~20 hr or 22°C for 8hrs, respectively. These kinesin domains are 
monomeric in solution. 
 Purification of HsEg5 began with lysing cells in lysis buffer (50 mM 
Na/Phosphate pH 6.8, 1 mM EDTA, 1 mM DTT, 1 mM AEBSF, 1 μM Leupeptin, 
Pepstatin, Benzamidine, 5 mM EDTA, 5 mM EGTA) by three or more passages 
through an Emulsiflex microfluidizer followed by clarification by ultracentrifugation 
at 35000rpm for 35 minutes.  The lysate was loaded onto a Hitrap SP column 
equilibrated in 50 mM Phosphate pH 6.8, 1 mM EDTA, 1 mM DTT and eluted by 
65ml gradient into 20 mM Phosphate pH 6.8, 1 M NaCl, 1 mM EDTA, 1 mM DTT.  
Fractions were pooled and diluted with 4 volumes of 50 mM Tris pH 8.5, 1 mM 
EDTA, 1 mM DTT buffer and loaded onto a MonoQ column.  After ~3 column 
volumes of washing, fractions were eluted by gradient into 20 mM Tris pH 8.5, 1 
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M NaCl, 1 mM EDTA, 1 mM DTT.  The pooled protein was then run on a 
superdex75 column in 20 mM PIPES pH 6.8, 125 mM KCl, 5 mM MgCl2, 1 mM 
DTT.  The resulting protein was >98% pure. 
Purification of DmKHC began with lysing cells in lysis buffer (25 mM Tris 
pH 8, 0.5M NaCl, 5 mM BME, 5% glycerol, 20 mM imidazole, 1 mM AEBSF, 1 
μM Leupeptin, Pepstatin, Benzamidine, 5 mM EDTA, 5 mM EGTA) by three or 
more passages through an Emulsiflex microfluidizer followed by clarification by 
ultracentrifugation at 35000rpm for 35 minutes.  The lysate was loaded onto a 
His-Trap column equilibrated in 25 mM Tris pH 8, 0.5M NaCl, 5 mM BME, 5% 
glycerol, 20 mM imidazole washed with 60 mM imidazole until UV absorbance 
stabilized and eluted in 300 mM imidazole.  Fractions were pooled and 
exchanged into 25 mM Tris pH 8, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 2.5% 
glycerol buffer and loaded onto a MonoQ column.  After ~3 column volumes of 
washing, fractions were eluted by 120ml gradient into 25 mM Tris pH 8, 1 M NaCl, 
1 mM EDTA, 1 mM DTT, 2.5% glycerol.  The pooled protein was then run on a 
superdex75 column in 20 mM PIPES pH 6.8, 125 mM KCl, 5 mM MgCl2, 1 mM 
DTT.  The resulting protein was >98% pure. 
Purification of HsKIF4B began with lysing cells in lysis buffer (25 mM Tris 
pH 8, 0.5M NaCl, 5 mM BME, 5% glycerol, 20 mM imidazole, 1 mM AEBSF, 1 
μM Leupeptin, Pepstatin, Benzamidine, 5 mM EDTA, 5 mM EGTA) by three or 
more passages through an Emulsiflex microfluidizer followed by clarification by 
ultracentrifugation at 35000rpm for 35 minutes.  The lysate was loaded onto a 
His-Trap column equilibrated in 25 mM Tris pH 8, 0.5M NaCl, 5 mM BME, 5% 
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glycerol, 20 mM imidazole washed with 60 mM imidazole until UV absorbance 
stabilized and eluted in 300 mM imidazole.  Fractions were pooled and diluted 
with 9 volumes 25 mM PIPES pH 6.8, 1 mM EDTA, 1 mM DTT buffer and loaded 
onto a MonoS column equilibrated in the same buffer plus 50 mM NaCl.  After ~3 
column volumes of washing, fractions were eluted by 120ml gradient into 50 mM 
PIPES pH 6.8, 1 M NaCl, 1 mM EDTA, 1 mM DTT.  The pooled protein was then 
run on a superdex75 column in 20 mM PIPES pH 6.8, 125 mM KCl, 5 mM MgCl2, 
1 mM DTT.  The resulting protein was >98% pure. 
Purification of MmKIF1A began with lysing cells in lysis buffer (25 mM Tris 
pH 8, 0.5M NaCl, 5 mM BME, 5% glycerol, 20 mM imidazole, 1 mM AEBSF, 1 
μM Leupeptin, Pepstatin, Benzamidine, 5 mM EDTA, 5 mM EGTA) by three or 
more passages through an Emulsiflex microfluidizer followed by clarification by 
ultracentrifugation at 35000rpm for 35 minutes.  The lysate was loaded onto a 
His-Trap column equilibrated in 25 mM Tris pH 8, 0.5M NaCl, 5 mM BME, 5% 
glycerol, 20 mM imidazole washed with 60 mM imidazole until UV absorbance 
stabilized and eluted in 300 mM imidazole.  Fractions were pooled and diluted 
with 9 volumes 25 mM Hepes pH 7.5, 1 mM EDTA, 1 mM DTT buffer and loaded 
onto a MonoS column equilibrated in the same buffer plus 175 mM NaCl.  After 
~3 column volumes of washing, fractions were eluted by 90ml gradient into 25 
mM Hepes pH 7.5, 1 M NaCl, 1 mM EDTA, 1 mM DTT.  The pooled protein was 
then run on a superdex75 column in 20 mM PIPES pH 6.8, 125 mM KCl, 5 mM 
MgCl2, 1 mM DTT.  The resulting protein was >98% pure. 
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 Purification of DmNcd began with lysing cells in lysis buffer (10 mM 
Phosphate pH 7.2, 0.1 M NaCl, 2 mM MgCl2, 1 mM DTT, 1 mM AEBSF, 1 μM 
Leupeptin, Pepstatin, Benzamidine, 5 mM EDTA, 5 mM EGTA) by three or more 
passages through an Emulsiflex microfluidizer followed by clarification by 
ultracentrifugation at 35000rpm for 35 minutes.  The lysate was loaded onto a 
Hitrap SP column equilibrated in 10 mM Phosphate pH 7.2, 0.1 M NaCl, 2 mM 
MgCl2, 1 mM EGTA, 1 mM DTT and eluted by gradient into 10 mM Phosphate 
pH 7.2, 1 M NaCl, 2 mM MgCl2, 1 mM EGTA, 1 mM DTT.  Fractions were pooled, 
dialyzed against 10 mM Tris pH 7.5, 80 mM NaCl, 2 mM MgCl2, 1 mM EDTA, 1 
mM DTT buffer and loaded onto a HiTrapQ column.  After ~3 column volumes of 
washing, fractions were eluted by 60ml gradient into 10 mM Tris pH 7.5, 1 M 
NaCl, 2 mM MgCl2, 1 mM EDTA, 1 mM DTT.  The pooled protein was then run 
on a superdex75 column in 20 mM PIPES pH 6.8, 125 mM KCl, 5 mM MgCl2, 1 
mM DTT.  The resulting protein was >98% pure. 
 
Crosslinking of kinesin microtubule binding domains 
 ~1 mg/ml DmKHC monomers were incubated for 20 minutes with 0.05-1 
mM BS3 crosslinker, 0.5 mM nucleotide (either ADP, AMPPNP, ATP, or and 
ADP/AMPPNP mixture), and ~2.5 mM tubulin (polymerized or depolymerized) 
where indicated.   The total reaction volume was 10ul.  The reaction buffer 
consisted of 50 mM PIPES pH 6.8, 5 mM MgCl2, 1 mM EGTA, and 1 mM DTT.  
Crosslinking reactions were quenched by addition of 2 ul 0.25 M Tris pH 7.4 for 5 
minutes and run on a 3-8% Tris-Acetate gel followed by visualization with 
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coomassie blue or western blotting against the C-terminal 6xhis tag of the KHC 
monomers. 
 
Concentration dependent kinesin ATPase activity assay  
 Purified kinesin monomers were serially diluted over a range of 10 µM to 
0.1 µM in reaction buffer (20 mM Pipes pH 6.8, 50 mM KCl, 1 mM DTT, 5 mM 
MgCl2, 0.2 mg/ml BSA) in an 8ul reaction volume.  Where indicated 12 μM 
microtubules were also included, either polymerized or depolymerized.  The 
reactions were initialized by addition of 2 µl 25 mM ATP, trace labeled with 
radioactive α-32P ATP.  After a short incubation (time varies based on activity 
level) the reactions were quenched with 100 mM EDTA and run on a TLC plate 
with the running buffer of 0.5 LiCl and 1 M formic acid.  Reactions were 
visualized by exposure to a storage phosphor screen and scanning on a 
Typhoon Trio (GE Healthcare), quantified using ImageQuantTL (GE Healthcare) 
software, and curve fitting was performed using Prism 5 (Graphpad) software.  
Reported errors are calculated standard error of the mean (SEM) from triplicate 
experiments.  For experiments with apparent sigmoidal activity profiles the data 
was fit with the equation Y=Bmax*X^h/(Kd^h + X^h), where Y is the activity, X is 
the protein concentration, Bmax is the maximal activity, and h is the hill 














9.1. Data collection and refinement statistics 
 
Table 4. Data collection and refinement statistics for static ternary complex 







Table 5. Data collection and refinement statistics for static ternary complex 








Table 6. Data collection and refinement statistics for time-resolved S113A 








Table 7. Data collection and refinement statistics for time-resolved S113A 










Table 8. Data collection and refinement statistics for time-resolved S113A 










Table 9. Data collection and refinement statistics for time-resolved WT Pol 









Table 10. Data collection and refinement statistics for Pol η in complex with 
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